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3D-CRT 3D-conformal chemoradiotherapy 
AKT serine/threonine protein kinase B 
BNCR Boron neutron capture therapy 
cD1 Cyclin D1 
CDK  Cyclin dependent kinase 
cN0 No clinically evident regional lymph node metastases 
cN+ Clinically evident regional lymph node metastases 
CRT Chemoradiotherapy 
CT Chemotherapy 
CUP Carcinoma of unknown primary 
DAMP Danger-associated molecular pattern 
DFS Disease-free survival 
DSS Disease-specific survival 
ENE Extranodal extension 
FDG-PET 18F-fluoro-2-deoxy-2-d-glucose positron emission tomography 
FNAC Fine-needle aspiration cytology 
Gy Gray 
H&E Hematozyline-eosine 
HNSCC Head and neck squamous cell carcinoma 
HPV Human papillomavirus 
HR High risk 
IHC Immunohistochemistry 
IMPT Intensity-modulated proton therapy 
IMRT Intensity-modulated radiotherapy 
ISH In situ hybridization 
LR Low risk 
MLC Multiple leaf collimator 
MRI Magnetic resonance imaging 
N+ Presence of regional metastasis (nodal metastasis) 
ND Neck dissection 
NF-B Nuclear factor kB 
OAR Organ at risk 
OP Oropharynx 
OPSCC Oropharyngeal squamous cell carcinoma 
OS Overall survival 
OTSCC Oral tongue squamous cell carcinoma 
p16 p16INK4A 
PAMP Pathogen-associated molecular pattern 
PCR Polymerase chain reaction 
pRB Retinoblastoma 
RFS Recurrence-free survival 
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RR Regional recurrence 
RT Radiotherapy 
SCC Squamous cell carcinoma 
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TMA Tissue microarray  
TNM Tumor node metastasis 
TORS Transoral robotic surgery 
  10 
&'%'
Head and neck cancers constitute the seventh most common cancer group 
worldwide. Their incidence has been declining in the Western world, along 
with the decrease in tobacco smoking. However, the incidence of 
oropharyngeal squamous cell carcinoma (OPSCC) has been rising over the last 
two to three decades in many Western countries. This trend is attributed to 
human papillomavirus (HPV), which is responsible for the majority of OPSCC 
cases, whereas, according to most reports, the incidence of HPV-unrelated 
OPSCC has decreased. If the current increasing trend continues, the incidence 
of OSPCC will surpass that of HPV-induced cervical carcinoma by the year 
2020. 
 
HPV-positive OPSCC differs from the HPV-negative form in various aspects: 
Patients typically have less tobacco and alcohol consumption. They tend to 
have smaller primary tumors but more advanced disease in the neck. In 
addition, their tumors usually have a higher histopathological grade, and 
several other biological differences, such as immunohistochemically 
detectable protein p16INK4A (p16) overexpression reflecting HPV positivity. 
 
Treatment for OPSCC typically includes either surgery and postoperative 
oncological treatment or definitive oncological treatment. Along with the 
increased incidence of OPSCC, the treatment modalities have also been 
changing towards a more non-surgical (organ-preserving) approach, later in 
this thesis referred to as an oncological approach, and the use of upfront 
surgery has been decreasing. In addition, according to some national 
protocols, the use of definitive oncological treatment, such as concurrent 
chemoradiotherapy (CRT), should be the principal method in OPSCC 
treatment, whereas surgery should be reserved for salvage purposes only. 
However, in some countries surgery has a more important role in OPSCC 
treatment.  
 
The increase in the proportion of patients carrying a HPV-positive tumor has 
created a demand to change treatment protocols, because within this patient 
group the response to CRT is typically markedly better than in patients 
carrying a HPV-unrelated tumor. Moreover, the long-term effects of the 
treatment may significantly reduce the patients’ quality of life. Patients with 
HPV-positive tumors are generally younger and they have better odds of 
survival, but their post-treatment lifetime may be harmed by major treatment-
related morbidity. Because of this, patients who carry a HPV-positive tumor, 
and are never-smokers, and have low T and N classes, may benefit from 
treatment de-escalation. Many prospective randomized trials delivering de-
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intensified treatment for this OPSCC patient group with the lowest risk of 
disease recurrence are currently ongoing. 
 
Validated predictive biomarkers could aid in the treatment individualization 
of OPSCC. Currently, many biomarkers besides HPV are suggested to be 
prognostic in OPSCC. However, the only well-validated prognostic biomarkers 
in OPSCC are HPV and protein p16. 
 
As OPSCC that carries an HPV association has an inflammatory background, 
innate immunity may play a significant role in disease etiology. Toll-like 
receptors (TLRs) are receptors, which recognize endogenous and exogenous 
molecular patterns. Their activation results in inflammation. In HPV-
associated cervical carcinoma, alteration in the expression of TLRs has been 
observed. These receptors are also expressed in an altered pattern when HPV 
infection persists in the cervix. Therefore, these receptors could have a role in 
HPV-associated OPSCC. 
 
The first part of the present study analyzed the treatment and outcome in two 
patient series treated over a ten-year period. Study I included all OPSCC 
patients treated at the Finnish university hospitals, and Study II focused on 
the management of the neck in cN+ disease of patients treated at the Helsinki 
University Hospital. Study I gathered population-based information on the 
treatment, outcome, and factors affecting the prognosis of OPSCC in Finland 
during the years from 2000 to 2009, when the treatment protocol was 
changing towards a more oncological approach. The cohort included 674 
patients, and during the study period, the incidence of this disease increased, 
which mainly occurred in the group of patients carrying a HPV-associated 
tumor. The outcome of lateral-wall OPSCC (tonsil) remained similar 
compared to an earlier Finnish nationwide report, but the outcome of 
anterior-wall disease (base of tongue) slightly improved. The factors 
contributing to an improved outcome in our patient cohort included female 
sex, p16 positivity, early T and N classes, and intensity-modulated 
radiotherapy (IMRT).  
 
The presence of neck metastasis has a significant effect on survival, and 
treatment of the neck remains one of the key issues in the management of head 
and neck cancer patients. Survival after regional recurrence is poor in OPSCC. 
Therefore, Study II analyzed the treatment provided for cN+ disease in a series 
of 201 patients. The relative rate of neck dissections (NDs) had decreased 
while the delivery of definitive CRT had increased. However, the regional 
control rate had not worsened. Regional failures occurred in patients with 
class cN2b or higher and they often developed on the contralateral side of the 
neck, including in patients with an ipsilateral primary tumor. Thus, according 
to our results, bilateral neck treatment is warranted in all patients having 
metastases in the neck in order to prevent regional failures.  
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The second part of this thesis study (Studies III and IV) evaluated the role of 
TLRs in OPSCC. As a pilot study, we analyzed TLR 2, 3, 4, 5, 7, and 9 
expression, p16 expression, and HPV status in 35 OPSCC samples. TLR 5, 7, 
and 9 expression varied according to p16 and HPV status. Among HPV-
positive tumors, TLR 5 and 9 were less expressed, and TLR 7 was more 
expressed. Cell-culture studies on OPSCC and oral tongue squamous cell 
carcinoma cell lines revealed similar results. Based on these results, we 
evaluated the association of TLR 5, 7, and 9 with clinicopathological and 
outcome data in a cohort of 202 OPSCC patients, which provided further 
support for our previous results. In addition, the findings indicated that high 
TLR 5 expression and low TLR 7 expression were related to poor disease-
specific survival in the group of HPV-positive OPSCC patients. 
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Pään ja kaulan syövät ovat maailman seitsemänneksi yleisin syöpätyyppi. 
Niiden esiintyvyys länsimaissa on laskenut tupakoinnin vähentyessä. 
Suunielusyöpä on kuitenkin yleistynyt monessa länsimaassa viimeisen 
muutaman vuosikymmenen aikana. Muutoksen taustalla on ihmisen 
papilloomaviruksen (HPV) aiheuttamien suunielusyöpätapausten merkittävä 
lisääntyminen, vaikka HPV:hen liittymättömän suunielusyövän esiintyvyys on 
laskenut. Mikäli taudin lisääntyminen jatkuu edelleen, sen on ennustettu 
ylittävän HPV:n aiheuttaman kohdunkaulan syövän esiintyvyyden vuonna 
2020. 
 
HPV-positiivinen suunielusyöpä eroaa monin tavoin HPV-negatiivisesta 
suunielusyövästä. Potilaat, jotka sairastuvat taudin HPV-positiiviseen 
muotoon, tyypillisesti tupakoivat vähemmän ja käyttävät vähemmän 
alkoholia. Lisäksi emokasvain on yleensä pienempi, mutta kaulalle on usein 
kehittynyt enemmän etäpesäkkeitä. Se on usein huonosti erilaistunut ja siinä 
on lukuisia molekyylibiologisia eroavaisuuksia, kuten 
immunohistokemiallisesti todettava proteiinin p16 vahva ilmentyminen, mikä 
liittyy HPV:n esiintymiseen kasvaimessa.   
 
Suunielusyöpä hoidetaan usein joko leikkauksen ja sen jälkeisten onkologisten 
liitännäishoitojen yhdistelmällä tai ns. definitiivisellä onkologisella hoidolla, 
jolloin leikkaus tehdään vain, jos potilaalla todetaan jäännöskasvain. Samalla 
kun suunielusyövän esiintyvyys on lisääntynyt, taudin hoitona on käytetty yhä 
useammin definitiivistä onkologista hoitoa. Suunielusyövän hoitomenetelmät 
vaihtelevat maittain. Joissakin maissa kansallinen hoitosuositus suosittaa 
ensisijaiseksi hoitomuodoksi kemosädehoitoa, kun taas toisissa maissa 
leikkaushoidolla on merkittävämpi osuus. 
 
HPV-positiivisen suunielusyövän lisääntyminen on luonut tarpeen muuttaa 
hoitosuosituksia, sillä kyseistä tautia sairastavilla potilailla vaste 
kemosädehoidolle on tyypillisesti parempi kuin virusnegatiivista tautia 
sairastavilla. Taudin hoidot ovat potilaille raskaita ja ne useimmiten 
heikentävät elämänlaatua. HPV-positiivista tautia sairastavat potilaat ovat 
usein nuorempia ja heillä on suurempi todennäköisyys välttyä taudin 
uusiutumalta, joten osa heistä joutuu kärsimään pitkään hoitojen jälkeisistä 
haittavaikutuksista. Hoitojen keventäminen HPV-positiivista tautia 
sairastavien kohdalla saattaa tarjota avun tähän ongelmaan. Meneillään on 
useita prospektiivisia satunnaistettuja tutkimuksia, joiden päämääränä on 
selvittää kevennettyjen hoitojen tehoa suunielusyövässä. 
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Kliiniseen käyttöön sopivien ennusteellisten biomerkkiaineiden löytäminen 
voisi mahdollistaa suunielusyöpäpotilaiden yksilöllisempien hoitojen 
suunnittelun. Tällä hetkellä monen biomerkkiaineen ennusteellista 
merkitystä tutkitaan tämän syövän suhteen, mutta ainoat validoidut 
ennusteelliset merkkiaineet ovat HPV ja proteiini p16. 
 
HPV:n aiheuttamassa suunielusyövässä on tulehduksellinen tausta, joten 
luonnollisella immuniteetillä voi olla merkittävä vaikutus taudin 
kehittymiseen. Tollin kaltaiset reseptorit (TLR) aktivoituvat kohdatessaan 
kehonulkoisia tai –sisäisiä molekyylirakenteita, mikä johtaa tulehdusreaktion 
kehittymiseen. HPV-infektion pitkittyessä kohdunkaulassa ja myös 
kohdunkaulan syövässä on todettu, että usean TLR:n ilmentyminen on 
poikkeavaa. Tällä perusteella voidaan olettaa, että TLR:llä voisi olla keskeinen 
merkitys myös suunielusyövässä.   
 
Tämän tutkimuksen ensimmäisessä osakokonaisuudessa analysoitiin vuosien 
2000-2009 aikana annettuja hoitoja ja hoitotuloksia kahdessa potilassarjassa. 
Ensimmäiseen osatyöhön oli kerätty kaikki Suomen viidessä 
yliopistosairaalassa hoidetut suunielusyöpäpotilaat. Toisessa osatyössä 
analysoitiin kaulan hoitoa HYKS:ssä potilailla, joilla oli diagnoosivaiheessa 
kaulalla etäpesäkkeet. Ensimmäinen osatyö selvitti tiedot 
suunielusyöpäpotilaiden hoidoista, hoitotuloksista ja ennusteeseen 
vaikuttavista tekijöistä. Tutkimusajanjakson aikana hoidettiin yhteensä 674 
potilasta. Tauti, ja erityisesti sen HPV:hen liittyvä muoto lisääntyi 
tutkimusajanjakson aikana ja definitiivinen onkologinen hoito toteutettiin yhä 
useammalle potilaalle. Aikaisempaan kansalliseen 
suunielusyöpätutkimukseen verrattuna nielun sivuseinämän (nielurisan) 
taudin ennuste oli pysynyt muuttumattomana, mutta nielun etuseinämän 
(kielen tyven) taudin ennuste oli hieman parantunut. Ennustetta parantavia 
tekijöitä olivat naissukupuoli, p16:n vahva positiivisuus, varhaiset T ja N 
luokat ja intensiteettimuokattu sädehoito.  
 
Kaulametastaaseilla on merkittävä vaikutus ennusteeseen. Tämän vuoksi 
kaulan hoidolla on keskeinen merkitys pään ja kaulan syöpäpotilaita 
hoidettaessa. Eloonjäämisen todennäköisyys on alhainen, mikäli 
suunielusyöpä uusiutuu kaulalla. Osakokonaisuuden toisessa osatyössä 
tutkimme kaulan hoitoa N+ taudissa. Kauladissektioiden suhteellinen määrä 
väheni samalla kun definitiivinen kemosädehoito yleistyi. Taudin 
uusiutumismäärät kaulalla eivät kuitenkaan lisääntyneet. Kaulan alueen 
uusiutumat kehittyivät potilaille, joiden kaulan kliininen luokitus oli N2b tai 
korkeampi ja ne kehittyivät usein emokasvaimen vastakkaiselle puolelle. 
Tulosten perusteella kaulan molemminpuolinen hoito on perusteltua kaikilla 
potilailla, joilla todetaan kaulametastaasi. 
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Tutkimuksen toisessa osakokonaisuudessa (osatyöt III-IV) tutkimme TLR:n 
merkitystä suunielusyövässä. Analysoimme ensin TLR 2, 3, 4, 5, 7 ja 9 sekä 
p16 ilmentymisen ja HPV-statuksen 35:sta suunielusyövästä. TLR 5, 7 ja 9 
ilmentyminen erosi p16-positiivisten ja –negatiivisten sekä HPV-positiivisten 
ja –negatiivisten suunielusyöpien välillä. HPV-positiivisissa kasvaimissa TLR 
5 ja 9 ilmentyminen oli vähäistä, kun taas TLR 7 ilmentyminen oli voimakasta 
verrattuna HPV-negatiivisiin kasvaimiin. Suunielusyövän ja suuontelosyövän 
soluviljelykokeissa todettiin vastaavanlaiset löydökset. Näiden tulosten 
perusteella selvitimme TLR 5, 7, ja 9 merkitystä laajemmassa 202 potilaan 
aineistossa verraten näiden proteiinien ilmentymistä potilaisiin ja tautiin 
liittyviin tekijöihin sekä taudin ennusteeseen. Tulokset vahvistivat aiempia 
löydöksiä. Sen lisäksi havaitsimme, että voimakas TLR 5 ja matala TLR 7 
ilmentyminen olivat yhteydessä korkeaan tautikuolleisuuteen HPV-
positiivista tautimuotoa sairastavilla potilailla.   
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The oropharynx (OP) is the middle part of pharynx, located at the level of the 
oral cavity, and between the nasopharynx and hypopharynx. The OP is 
typically divided into four walls, of which anterior wall includes the base of 
tongue and vallecula, the lateral wall includes the palatine tonsils and tonsillar 
pillars, the superior wall includes the uvula and inferior surface of the soft 
palate, and the posterior wall includes the mucosa between the nasopharynx 
and hypopharynx. (1)  
 
Patients with oropharyngeal cancer may initially be asymptomatic, but when 
symptoms are present, and at advanced stage, these typically include a sore 
tongue or throat, difficulties or pain in swallowing, ear pain, and a change in 
the voice. Often, a lump on the neck is the only presenting symptom or sign. 
(1)  
 
Worldwide malignancies arising from the head and neck are the seventh most 
common group of malignancies (2). The incidence of head and neck squamous 
cell carcinomas (HNSCCs) has been slowly declining while a simultaneous 
decrease has occurred in the most important risk factor, tobacco exposure (3). 
The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has, 
however, been rising in many Western countries (3-10). This trend is mainly 
attributed to the etiological involvement of human papillomavirus (HPV) in 
OPSCC (5, 11, 12). HPV-associated OPSCC differs from their HPV-negative 
counterparts in many respects. Patients with HPV association are typically 
younger, have fewer comorbidities, and have a higher socioeconomic status 
(11, 13). In addition, their disease is more advanced in terms of staging (UICC 
and AJCC 7th version) (14) and their tumors have a histologically higher grade 
of differentiation (15). However, their disease is typically more sensitive to 
treatment, regardless of treatment modality, and they have better survival 
(16). As these patients are expected to have a longer post-treatment lifetime 
than HNSCC patients in general, new treatment strategies are warranted in 
order to avoid treatment-related morbidity and toxicity without worsening the 
rates of disease control (17). Although patients with HPV-positive OPSCC have 
a better outcome, and HPV-negative OPSCC patients may benefit from 
primary surgery (18, 19), it has been stated that the modification of treatment 
according to HPV status needs to be avoided outside the context of 
randomized controlled trials (20-22). However, there is considerable interest 
in tailoring treatment also according to HPV status, as survival differs between 
HPV-positive and negative disease. OPSCC patients can also be divided into 
three groups with distinct survival rates, and the group of patients with the 
lowest risk of death are possibly suitable for treatment de-intensification (14). 
Besides HPV status, stratification is based on smoking status or a comorbidity 
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index, and T and N classes (14, 23). Furthermore, the latest TNM 
classifications of OPSCC patients divide them into two distinct subgroups 
according to the status of p16INK4A (p16) (24, 25), a surrogate marker reflecting 
HPV status (26). 
 
Along with the increasing incidence of HPV-positive OPSCC, the treatment 
paradigm has changed towards a more oncological approach (27, 28). Some 
national OPSCC treatment protocols suggest that definitive oncological 
treatment should be the principal treatment modality for OPSCC, and surgery 
should be used for salvage purposes only (29, 30). However, some other 
national protocols recommend both an oncological approach and upfront 
surgery (20, 22). 
 
Due to the inflammatory background in HPV-positive OPSCC, host 
immunological responses may be different in this form of disease: enhanced 
immune surveillance with virus-specific antitumor activity has been shown to 
occur in HPV-related HNSCC (31, 32). Studies on HPV-induced gynecological 
cervical cancer may offer information regarding the interplay between 
immunity and cancer. Persisting HPV infection has been shown to interfere 
with the expression of toll-like receptors (TLRs), the key activators of innate 
immunity, (33). In addition, TLR expression and TLR activity display 
modulations in the cervix during cancerous progression and in cancer (34, 35) 
. The role of TLRs in cancer has been shown to be twofold, because on the one 
hand they mediate antitumor activity, but on the other hand, they may 
promote carcinogenesis and tumor progression (36). 
 
This study aimed at evaluating the treatment provided and factors affecting 
the outcome of OPSCC patients in Finland. Management of the neck was 
considered in more detail. Furthermore, this study aimed at examining the 
expression and prognostic role of TLRs in OPSCC. 
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Head and neck cancer is the seventh most common cancer group in both sexes, 
with almost 700 000 people affected annually worldwide (2). Squamous cell 
carcinomas (SCCs) account for more than 90% of head and neck malignancies 
and their most important risk factors are cigarette smoking and heavy use of 
alcohol (37). Even though the trend in cigarette smoking has declined over the 
past decades (38), the incidence of head and neck squamous cell carcinomas 
(HNSCCs) for most sites has not changed or has only slowly declined (3, 5, 8). 
However, in the OP, the incidence of SCCs has predominantly risen in many 
countries worldwide (3-10), with the highest risk for HPV prevalence in 
Western Europe (39). The evolved epidemiologic profile of OPSCC is 
attributed to oncogenic high-risk (HR) Human papillomaviruses (HPV): In 
the US, the incidence of HR-HPV-related OPSCC increased by 0.80% annually 
from 1974 to 2004, while the incidence of HR-HPV-unrelated OPSCC 
decreased during the same period (11). Notably, it has been estimated that the 
incidence of HR-HPV-related OPSCC will surpass that of HR-HPV driven 
cervical cancer by the year 2020 (5). In Sweden, the rise in the incidence of 
HR-HPV-associated OPSCC may be stabilizing (40). However, a recent 
publication suggests a parallel increase for HR-HPV-positive and HR-HPV-
negative OPSCC in the United Kingdom (41). 
 
In Finland, detailed information on the incidence of OPSCC is still lacking. 
However, the incidence of pharyngeal cancer (C01, C09-14) has clearly risen 
since 1968 among males, while over the same period, the incidence among 
females has remained stable (42) (Figure 1). The male-to-female ratio for the 
incidence of pharyngeal cancer was 1.7 between 1968 and 1987, 2.7 between 
1988 and 2012, and as high as 4.0 in the year 2014. The patient demographics 
of OPSCC have altered in the course of the HPV-era: HR-HPV-related OPSCC 
patients are characteristically younger, and more often male and white than 
patients with HR-HPV-unrelated OPSCC (11).  
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Figure 1. Annual number of new pharyngeal cancer patients (C01, C09-C14) 
separately for men and women in Finland from 1968 to 2014 (42).  
 
Oropharyngeal HR-HPV infection is most likely responsible for the 
development of HR-HPV-related OPSCC, as the prevalence of oncogenic HR-
HPV is significantly higher in OPSCC patients than in healthy controls (43, 
44). Among the male population, the overall incidence of oral HR-HPV 
infection is reportedly 1.7%, and infections typically clear within one year (45). 
Evidently, active smoking delays the clearance of oral HR-HPV infection (46, 
47). Uncleared oral HR-HPV infections are associated with a risk of developing 
HR-HPV-related OPSCC (48, 49). The reason why males and whites are at 
greater risk of HR-HPV infection is probably associated with sexual behavior: 
a high number of oral sexual partners increases the odds of oral HR-HPV 
infection (50). The demographic profile of HR-HPV-related OPSCC patients 
differs from those with a HR-HPV-unrelated OPSCC. Those patients who carry 
a HR-HPV-positive tumor are typically younger, more probably male, and 
have a higher socioeconomic status compared with those who have a HR-HPV-
negative tumor (11, 13). Recent literature, however, conflicts with the 
viewpoint that HPV is merely a sexually transmitted disease. It has been 
shown that sexually inexperienced children also carry HR-HPV-specific cell-
mediated immunity (51, 52). Furthermore, the first HR-HPV infection may 
occur during the fetal period, which may predispose to a prolonged skew in the 
balance of Th1- and Th2-mediated immune responses, possibly resulting in 
persistent HR-HPV infection. Another suggested course for HR-HPV 
persistence is a specific defect in the immune system. (53) 

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HR-HPV-positive OPSCC typically develops in the palatine tonsils or in the 
base of tongue, whereas the prevalence of HR-HPV in superior wall or 
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posterior wall tumors is significantly lower (54). Tonsillar tissue has a 
significant role in the development of OPSCC. The structure of the palatine 
and lingual tonsils includes a surface layer and crypts, which are histologically 
distinct. HR-HPV-positive OPSCC typically develops in the crypts, where the 
epithelium captures and processes antigens, thereby facilitating the entry of 
HR-HPV into basal cells. HR-HPV-negative OPSCC instead develops in the 
surface layer of the tonsils (55). 
 
The development of OPSCC largely relies on the abnormal activity of two 
intracellular cascades, the first involving protein p53, and the second involving 
proteins p16INK4A (p16), cyclin D1 (cD1), cyclin dependent kinases (CDKs), and 
retinoblastoma (pRB) (Figure 2).  
 
The p53 protein, first described in 1979, is a transcription factor, which acts as 
a tumor suppressor. It is activated by cellular stress, such as DNA damage, 
telomere shortening, oxidative stress, and hypoxia. p53 activity may lead to 
DNA repair and cause transient growth arrest, but severe cellular stress may 
also lead to senescence and apoptosis (56).  
 
In the other cascade typically involved in OPSCC, under-phosphorylation of 
pRB keeps transcription factor E2F unreleased, thereby regulating the G1/S 
checkpoint. Upstream of these proteins, p16 suppresses and cD1 activates 
CDKs, which act by phosphorylating pRB (57).   
 
These pathways are perturbed both in HR-HPV-unrelated (58) and HR-HPV-
related OPSCC (59), but the underlying mechanisms are different as presented 
in Figure 2. In addition, HR-HPV markedly affects to the genetic landscape of 
OPSCC: The rate of mutations in HR-HPV-positive OPSCC is typically half that 
in HR-HPV-negative counterparts (60).  Thus, it has been suggested that HR-
HPV-related OPSCC comprises a distinct disease entity (15).  
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Figure 2. Cancerous pathways in HR-HPV-negative and HR-HPV-positive 
oropharyngeal squamous cell carcinoma.  
A: A mutation in p53 leads to the loss of its tumor-suppressing function. 
Cyclin D1 amplification, and a deletion in p16 increase the activity of CDK4. 
CDK4 phosphorylates pRB, which loses its repressive function on E2F. 
Inhibition of apoptosis and cell cycle progression results from p53 inactivity 
and E2F activation.  
B: Proteins E6 and E7 of HR-HPV are carcinogenic. E6 binds p53, causing 
p53 degradation. E7 binds pRB in a phosphorylation-independent manner, 
causing E2F release and activation. Inhibition of apoptosis and cell cycle 
progression results from p53 degradation and E2F activation. 

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Studies have shown that risk factors such as smoking of tobacco (14) and heavy 
drinking of alcohol (15) are strongly associated with HPV negativity in OPSCC. 
In addition, poor oral and dental hygiene have been recognized as independent 
risk factors (61). The key genetic alterations in this form of disease are as 
follows: a mutation in tumor suppressor gene TP53 encoding p53, a deletion 
in tumor suppressor gene CDKN2A/B encoding p16, and amplification in 
proto-oncogene CCND1 encoding cD1 (59). Figure 2A illustrates the 
pathogenesis of HPV-negative OPSCC. A cell with a TP53 mutation suffers 
from a loss of p53 function, leading to events such as the disruption of DNA 
repair, growth arrest, and apoptosis  (56). A deletion in CDKN2A/B leads to 
the loss of p16, ending the negative regulation of CDKs. Amplification in 
CCND1 causes increased transcription of cD1, and increased activation of 
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CDKs. This activation of CDKs eventually leads into pRB phosphorylation and 
E2F activation (59). 
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HPV is an enveloped, non-capsuled double-stranded DNA virus with 210 
currently known subtypes (62). The subtypes are further classified into HR 
and low-risk (LR) subtypes on the basis of their carcinogenic potential (63). In 
OPSCC, the most important HR-HPV subtype is HPV16, which accounts for 
nearly 90% of all HR-HPV-positive OPSCC cases, whereas the involvement of 
HPV18, and other HR-HPV subtypes is rare (64). During HR-HPV infection, 
the viral genome is integrated into the genome of the host cell, but HR-HPV-
DNA can also act intracellularly as an episome. The genome of HPV carries 
oncogenes, of which E6 and E7 are the most important in the carcinogenesis 
of HR-HPV-related OPSCC. Both HR-HPVs and LR-HPVs carry these proteins 
in their genome, but only HR-HPV E6 and E7 have a high affinity for tumor 
suppressor proteins (65). Oncoprotein E6 binds to p53 and marks it for 
degradation, thereby preventing its normal function, as presented in Figure 
2B. E6 may also cause telomerase activation, leading to immortalization of the 
infected cell. Oncoprotein E7 binds to and inactivates pRB in a 
phosphorylation-independent manner, leading to the cessation of its 
repressive function on E2F. Because of this perturbation, a solution is pursued 
but is not reached by overexpressing p16 in order to prevent the 
phosphorylation of pRB. (58) A common mutation occurring in 24% to 31% of 
HR-HPV-related OPSCCs is a PIK3CA mutation causing PIK3 protein 
activation, the clinical importance of which remains incompletely understood 
(66-68). In addition, it has been reported that mutations in the gene encoding 
tumor necrosis factor receptor-associated factor 3 (TRAF3) protein are unique 
to HR-HPV-associated OPSCC (69). 
 !"&&
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Oropharyngeal malignancies may be asymptomatic. When present, symptoms 
may include a sore tongue or throat, difficulties or pain in swallowing, voice 
change, and ear pain. A lump on the neck is a common initial clinical finding. 
Other signs include an ulcerated or exophytic mass in the pharynx or an 
enlarged tonsil. (1)  
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A routine clinical otorhinolaryngological examination is supplemented with 
endoscopy of the upper aerodigestive tract at an out-patient clinic and under 
general anesthesia when required in order to evaluate the extent of the disease. 
The primary tumor is biopsied in the course of an appointment when possible, 
but particularly in anterior-wall tumors, biopsy under anesthesia may be 
required.  Imaging of the primary site and neck generally includes either 
magnetic resonance imaging (MRI), or computer tomography. Soft tissue 
spread is better discerned with MRI, but computer tomography is better in 
evaluating the degree of bony invasion (70, 71). Diffusion-weighted MRI may 
enable the discrimination of malignant tissues from non-malignant, and SCCs 
from other malignancies. In addition, it may be used to detect small cervical 
lymph node metastasis, distinguish necrotic tissue from viable and post-
treatment changes from tumor tissue, and even predict the treatment 
response. (72) Potential distant spread and second primary tumors are 
generally detected with computer tomography of the thorax and upper 
abdomen. 
 
Carcinoma of unknown primary (CUP) presents in 2–3% of HNSCC patients 
with cervical lymph node metastasis (73). Up to 90% of cases with subsequent 
primary tumor identification may originate from the OP (74). If fine-needle 
aspiration cytology (FNAC) from a cervical lymph node reveals signs of SCC 
with positive p16 staining, the primary tumor is most probably located in the 
OP (75). According to Danish guidelines (76), which are similar to Finnish 
practice, if a lump on the neck is the only sign, ultrasound with FNAC is 
performed. In the case of SCC suspicion in FNAC, the location of the primary 
tumor is sought using 18F-fluoro-2-deoxy-2-d-glucose positron emission 
tomography (FGD-PET) computer tomography. FDG-PET computer 
tomography is followed by tonsillectomy, pharyngo-laryngoscopy, and upper 
esophagoscopy, and sometimes with other endoscopic procedures. FDG-PET 
can also be applied with MRI (77). Narrow band imaging can be used to 
improve the detection of upper airway lesions (78). If a primary tumor is not 
detected after panendoscopy and tonsillectomy, transoral robotic surgery 
(TORS) in the identification of base of tongue tumors may be beneficial 
especially in cases with p16-positive metastases: a study reported that the 
primary tumor originated in the base of tongue in 78% of such cases (76). If 
the primary tumor is identified using TORS, the pathologic staging is enabled 
and the requirement for oncological treatment can be estimated more 
accurately (76). 
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In addition to normal hematoxylin-eosin (H&E) staining of formalin-fixed 
samples, p16 immunohistochemistry reflecting HR-HPV involvement (26) is 
also nowadays routinely performed from OPSCCs. The HR-HPV status can be 
directly detected using the HPV polymerase chain reaction or HPV in situ 
hybridization (ISH), which are discussed in more detail later. Surgical 
resection samples provide information on tumor size, margins, the depth of 
invasion, angioinvasion and perineural invasion, and the number and size of 
lymph node metastases and their extranodal extension (ENE).  
 &'!
 
Clinical TNM staging, based on the primary tumor, regional lymph node 
metastasis, and distant metastases for OPSCC according to UICC and AJCC 
7th edition, is presented in Table 1. The 8th edition of UICC and AJCC TNM 
staging for OPSCC, published in 2016, separately evaluates the extent of HR-
HPV-related and HR-HPV-unrelated OPSCC based on p16 overexpression 
status (Table 2). The updates to the staging system include new T and N 
classifications for p16-positive OPSCC, and renewed N classification for all 
p16-negative HNSCCs. In addition, the clinical and pathologic classification 
for p16-positive OPSCC are markedly different. 
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Early-stage OPSCC can usually be managed with single-modality treatment. 
Advanced-stage disease requires multimodality treatment, which has typically 
consisted of a combination of surgery and postoperative radiotherapy (RT) or 
CRT. The treatment modality for the neck is usually the same as that for the 
primary site. However, definitive oncological treatment, also known as organ-
sparing treatment, currently has a significant role in this setting. This method 
is complemented by salvage surgery in cases of residual or recurrent disease. 
(1)  
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A decisive step in neck management is to evaluate whether the neck is 
clinically classified as N0 (cN0) or N+ (cN+). Elective neck treatment is 
typically delivered if the risk of neck metastasis exceeds 20%, and it can consist 
of either an elective neck dissection (ND), or elective RT. (81) Most OPSCC 
patients are diagnosed with cN+ status requiring therapeutic treatment (82). 
Furthermore, even in most OPSCC patients with cN0 status, the estimated risk 
of metastasis exceeds a level requiring neck treatment (82). An exception to 
this are e.g. patients with T1N0 soft palate tumors with a lower risk of 
metastasis and in whom a sentinel lymph node biopsy (SNLB) may also be an 
option to evaluate the neck status more accurately (83, 84). 
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Surgery is an option for the majority of oropharyngeal tumors, but indications 
for resection largely depend on factors such as the tumor site, and the expected 
impact of treatment on patient function and quality of life. A 1–2 cm margin 
of healthy tissue has to be taken into the resection specimen with an aim to 
achieve a minimum of 5 mm microscopical margins, which in advanced 
tumors leads to large defects. Reconstruction for a large defect is typically 
performed with a microvascular free tissue transfer, such as an anterolateral 
thigh flap or a radial forearm flap. Most small tumors can be operated 
transorally, and larger ones require wider open exposures through the neck, 
and sometimes mandibulectomy. (1) TORS is an alternative, especially in the 
resection of small or moderate-sized base of tongue tumors (85).  
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The extent of ND depends on the primary tumor site and T class, as well as N 
class. However, the exact levels that should be included in the ND are to some 
extent debatable (1, 86). Elective ND, which generally includes levels I–IV in 
OPSCC, also provides valuable pathologic information regarding regional 
disease, which may influence the treatment intensity (81). In cN+ disease, 
levels I-V should generally be dissected (1). The risk of contralateral nodal 
involvement is increased if T class is T4 or N class is N2a or higher (82). Lim 
et al. have recommended that if tonsillar SCC is classified as T3 or higher, and 
the patient presents with ipsilateral metastasis, contralateral ND should also 
be performed (87). 
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Treatment response and the need for surgical salvage for a residual tumor after 
definitive oncological treatment are currently evaluated with PET-CT at 3–4 
months after treatment completion, as the rate of false-positive and possible 
false-negative findings may be higher if PET-CT is performed earlier (88). A 
negative PET-CT is, however, fairly reliable, with a negative predictive value 
around 95% (89). If PET-CT shows activity at the primary site, biopsies should 
be taken to confirm or exclude residual disease. A positive finding on the neck 
in PET-CT is an indication for ND. (89, 90) A proportion of post-treatment 
PET-CT scans are classified as equivocal. In these cases, qualitative 
interpretation using a Likert scale may enable the possibility of residual 
disease to be ruled out (91). It has also been suggested that imaging findings 
could determine the extent of salvage NDs, which would then in most cases 
include levels II–IV, whereas dissection of levels I and V should be based on 
pathological findings in images (92, 93). The extent of salvage surgery of the 
residual or recurrent tumor is planned according to the dimensions of the 
primary tumor before CRT, often requiring large resections (94, 95). In 
oropharyngeal tumors, however, the radicality of the salvage resection may 
sometimes be limited because of the close proximity of vital structures such as 
the internal carotid artery and skull base, and this possibly accounts for 
inferior cure rates reported for local residual OPSCC compared with local 
residual hypopharyngeal SCC (94).  
 
The rate of complications is particularly high after salvage surgery (94, 96), 
and patients have a high risk of a significant loss of function (97). Salvage 
surgery for recurrences does not particularly differ from salvage surgery 
performed for residual tumors, and survival in both patient populations 
remains poor (94).  
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Ionizing radiation damages DNA and causes cell death in all tissues, which is 
why RT should be extremely tumor selective. In addition, the supply of oxygen 
has a considerable impact on RT efficacy, and hypoxia may reduce the 
effectiveness of RT (98), but also increase the likelihood of invasion and 
metastasis due to increased angiogenesis (99).  
 
The delivery of RT for head and neck tumors is complicated because of the 
close proximity of surrounding organs at risk (OAR), such as major salivary 
glands, the spinal cord, brainstem, optic nerve, pharyngeal muscles, and vocal 
cords. In the early 1990s, the 3D conformal RT (3D-CRT) method was 
introduced. This technique utilizes computer tomography images in dose 
planning, but the radiation intensity is typically the same across the field or 
modified with wedges or compensating filters. The shape of the beam is 
determined using either customized blocks or multiple leaf collimators (MLC). 
In IMRT, introduced during the late 1990s, computer-assisted determination 
of the radiation dose to the tumor is applied utilizing multiple radiation beam 
directions, beam intensity modulation with dynamic MLCs, and other devices. 
This method enables the delivery of a higher radiation dose to the tumor with 
lower dose to OAR compared with the 3D-CRT. IMRT, however, requires more 
labor in the planning phase and is more expensive. (100) Proton therapy, 
which is not yet available in Finland, may offer advantages in head and neck 
cancer treatment, as the greatest part of the energy is released at a defined 
depth. When proton therapy is delivered from different beam angles, the 
method is termed intensity-modulated proton therapy (IMPT). (101) 
 
RT is given in daily fractions. The fractionation of RT may be conventional, 
accelerated, or hyperfractionated. In conventional fractionation, a daily dose 
of 2 gray (Gy) is delivered for five days followed by a break of two days. 
Generally, the conventional RT takes six to seven weeks to complete. In the 
accelerated form, the intervals between RT are shortened without a significant 
change in the single dose or total dose. In hyperfractionated RT, single doses 
are reduced and the intervals between treatment sessions are shorter without 
a significant difference in the total treatment time or total dose. (102) In 
Finland, conventional fractionation is most commonly used.  
 
In definitive oncological treatment, depending on tumor-related factors such 
as the tumor stage, patients receive a total dose between 66 and 70 gray (Gy). 
The involved regional lymph nodes and high-risk areas are treated with a total 
dose of 60-70 Gy. The elective dose is 50 Gy. (100)  
   31
After primary surgery, most patients require postoperative oncological 
treatment. The postoperative RT dose to high-risk areas is typically 60–66 Gy. 
For intermediate-risk areas, this dose is approximately 60 Gy. Elective areas 
are treated with a total dose of 50 Gy. (100) 
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In relation to RT, CT may be neoadjuvant, concomitant, or adjuvant. In 
neoadjuvant treatment, CT is administered before the main treatment in order 
to reduce the tumor volume to facilitate more effective treatment (103). 
Neoadjuvant CT is, however, rarely used in OPSCC treatment in Finland. The 
benefit of concomitant CRT has been shown to be higher than neoadjuvant CT 
(104). In Finland, the most commonly used CT agent in concomitant CRT is 
weekly Cisplatin 40 mg/m2 (Guidelines of the Finnish Head and Neck 
Oncology Working Group). Cisplatin 100 mg/m2 every third week, 
carboplatin, 5-fluorouracil, and paclitaxel are seldom-used CT agents. A 
biological agent, such as cetuximab, may also be used. (100) 
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Immune-based treatment for HNSCCs has been introduced during recent 
years, as understanding of the immune system’s role in the development of 
cancer has been increasing. Immunotherapy strategies for HR-HPV-positive 
and HR-HPV-negative are suggested to be different (105). In HR-HPV-
positive OPSCC, viral oncoproteins E6 and E7 present as optional targets for 
treatment, as they are expressed in the tumor cells, and their suppression may 
restore the activity of suppressed p53 and pRB (106). Currently, therapeutic 
vaccination is the most examined immune-based treatment method for HR-
HPV-positive OPSCC. Therapeutic vaccines may contain DNA or peptides. In 
addition, the patient’s own dendritic cells can be maturated and activated 
(dendritic cell vaccine) ex-vivo to enhance anti-tumor immunity, or the 
patient’s own tumor-specific T-cells can be cultured ex vivo and thereafter 
transferred back into the patient (adoptive T cell transfer). (105) In the 
treatment of patients with HR-HPV-negative OPSCC, the use of monoclonal 
antibodies has been studied. In addition, immune checkpoint inhibitors, such 
as anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies are currently being 
investigated, as well as dendritic cell vaccine and adoptive T cell transfer. (105) 
Recently, it has been shown that treatment of recurrent HNSCC using anti-
PD-1 antibody therapy results in longer survival than after treatment with 
standard therapy (107). In addition, it has been shown that treatment of 
recurrent HNSCC with another anti-PD-1 antibody, pembrolizumab, is well 
tolerated and may result in feasible treatment response (108, 109).  
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In Finland, the multidisciplinary National Head and Neck Oncology Working 
Group maintains and updates national treatment guidelines for HNSCC. The 
treatment of OPSCC with curative intent in Finland may follow the both of the 
two main patterns: primary surgical treatment with or without postoperative 
oncological treatment or, alternatively, definitive oncological treatment with 
salvage surgery when needed. The treatment decision is recommended 
individually by a multidisciplinary tumor board, and it depends on both 
patient-related factors, such as comorbidities, performance status, 
compliance, and the patient’s own wish regarding treatment, and on tumor-
related factors such as the extent of disease (TNM) and site. In addition, 
institutional resources and experience also have an impact in the treatment 
decision. (Guidelines of the Finnish Head and Neck Oncology Working 
Group). 
 
Generally, small tumors, such as T1-T2 tonsillar SCCs, may be treated with 
upfront surgery followed by adjuvant treatment rather than with definitive 
oncological treatment in order to avoid long-term adverse sequelae such as 
xerostomia. However, patients with larger tumors, such as T4 base of tongue 
SCCs, would most probably have a markedly reduced quality of life when 
treated with upfront surgery compared with definitive oncological treatment. 
(110) In superior-wall tumors, if more than half of the soft palate has to be 
reconstructed after resection, the speech outcome is considerably worse (111). 
Zelefsky et al. (112) reported that quality of life related functional loss after 
upfront surgery is significantly higher if the primary tumor is classified as T3-
T4 and if the tumor originates from the base of the tongue. In their surgically 
treated series, the List (113) performance rates for eating in public, 
understandability of speech, and normality of diet were lower (112) than in 
another series treated with definitive oncological therapy for base of tongue 
SCC (114). However, a recent systematic review evaluating the swallowing 
outcome after a trans-oral surgical approach and after definitive oncological 
treatment concluded that according to the current evidence, direct head-to-
head comparisons of the swallowing outcome between these two modalities 
cannot be made (115). An ongoing study, “Phase II Randomized Trial for Early-
stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-
oral Robotic Surgery” (116), may provide valuable information regarding the 
differences in the functional outcomes after these treatment modalities.  
 
It has to be taken into account that treatment guidelines for OPSCC vary 
between countries. In Sweden, definitive oncological treatment with salvage 
surgery when necessary is considered as the principal treatment method, but 
primary surgery can be considered for T1 superior wall tumors, T1-T2 tonsil 
and base of tongue tumors (29). In Denmark, the DAHANCA guidelines 
suggest only a definitive oncological approach, and surgery is preserved as a 
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salvage modality (30). In the United Kingdom and the US, primary surgery or 
radiotherapy alone can be considered for early-stage (I-II) OPSCC. Advanced-
stage (III-IVb) OPSCC may include either combination treatment, i.e. surgery 
and postoperative oncological treatment, or definitive oncological treatment 
with salvage surgery if necessary. (20, 22)  
 
The variation in treatment probably reflects the lack of consensus regarding 
the optimal treatment. OPSCC etiology has been rapidly changing over the two 
last decades, and evidence for the optimal treatment is thus lacking. Parallel 
comparisons of survival outcomes after primary surgical treatment and 
definitive oncological treatment in randomized-controlled prospective studies 
are lacking, but separate studies have shown similar outcome figures after 
these two treatment modalities (14, 110, 117-119). However, the rates of severe 
and fatal complications after upfront surgery are strikingly higher in tonsillar 
SCC, and especially in base of tongue SCC, when compared with definitive 
oncological treatment (110). HR-HPV status is the factor affecting to the 
survival at the most, but many authors have recommended, at least so far, that 
modifying the treatment according to HR-HPV status in clinical practice 
should be avoided, as sufficient evidence for how the treatment should differ 
is still lacking (20-22). However, there is a growing interest in tailoring 
treatment according to HR-HPV status, as it has been reported that patients 
carrying HR-HPV-negative OPSCC may benefit more from primary surgery 
than definitive oncological treatment (18, 19), and some patients carrying HR-
HPV-positive tumors may be suitable for treatment de-escalation (14). It is 
also noteworthy that the latest TNM classification is different for p16-positive 
and p16-negative OPSCC (24, 25). 
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Definitive oncological treatment and surgery combined with oncological 
treatment have both been alternately considered as the optimal treatment 
modalities for OPSCC from the early 20th century, and the paradigm shifts 
have often been attributed to advances in technology (120). From the late 
1990s onwards at many institutions, upfront surgery was considered a 
secondary option, as developments in RT and CT improved survival and 
reduced treatment-related morbidity. According to a national cancer database 
in the US, during the years 1985–2001, surgery was performed for 27–28% of 
all OPSCC patients, while the use of definitive CRT had increased from 15% to 
29% (27). In Finland, during 1995–1999, primary surgery was performed for 
85.4% of OPSCC patients, and definitive oncological treatment was given to 
only 14.6% of the patients (121). From 1998 to 2009, OPSCC treatment 
changed in the US, as the surgical treatment declined from 41% to 31%, and 
the use of definitive CRT increased from 22.4% to 61.5% (28). Another report 
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showed that a 2.4-fold decrease in primary surgical treatment and a 4.5-fold 
increase in CRT occurred in the US between the periods of 1955–1994 and 
1995–2004 (122). Definitive oncological treatment became described as an 
organ-preserving therapy, and it was introduced to offer an advantage in 
functional outcome, as the tumor sites remain without surgical intervention 
for those who do not develop residual or recurrent disease (123). In OPSCC, a 
two-year rate of 84% in organ preservation after definitive CRT has been 
reported (124). However, a minimally invasive approach in upfront surgery is 
currently increasing, and a resection can be carried out using TORS. This 
method aims at reducing the morbidity related to traditional open approaches 
without worsening survival. Offering surgery as a treatment option also carries 
an advantage in terms of obtaining a pathological analysis of the disease. As 
the extent of disease is revealed, adjuvant treatment planning can be 
considered after surgery, based on the marginal status, pathological T and N 
staging, and ENE. In addition, after upfront surgery, the dose of RT may be 
lower and CT can be avoided in some cases. (125)  
 
After definitive CRT, using older 2D- and 3D-RT techniques, the risk of various 
severe late toxicities may be as high as 12.6% for feeding tube dependence, and 
39.6% for laryngeal or pharyngeal dysfunction (126). Importantly, there is 
evidence that salivary gland function can be well preserved after IMRT without 
jeopardizing disease-control rates (127, 128). In addition, in OPSCC, IMRT 
compared with 3D-CRT offers better long-term results in functional outcome, 
such as swallowing, with no difference in survival (129). Furthermore, in the 
treatment of OPSCC, IMPT has been shown to reduce feeding tube 
dependency and severe weight loss without jeopardizing survival (130). 
 
Re-irradiation of head and neck cancer has traditionally resulted in a markedly 
high rate of late toxicities such as trismus, osteoradionecrosis, mucosal 
necrosis, and ultimately even carotid hemorrhage (131). However, delivering 
IMRT-based re-irradiation has provided a less toxic approach to pursue a cure 
for head and neck cancer (132). In addition, boron neutron capture therapy 
(BNCT) has been studied in the treatment of inoperable and irradiated locally 
recurrent head and neck cancer (133). 
 
CT is delivered to radio-sensitize the tumor, but also to reduce the risk of 
distant failure. CT agents have however, several adverse effects. The most 
commonly used agent, cisplatin typically causes nausea, but also toxicity in the 
nervous system, kidneys, inner ear (134), and bone marrow (135). Another 
common CT agent, cetuximab, typically causes rash, mucositis, nutrition 
impairment, hypomagnesemia, and infusion reactions (134).  
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Non-curative treatment always aims at palliating the patient’s symptoms. In 
selected cases, slowing down the progression of the disease may also be 
pursued. Treatment approaches may include methods also used in curative 
treatment, such as RT, CT, or surgery (136). 
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Survival has markedly improved among HNSCC patients since the 1980s, with 
biggest improvement in tonsillar carcinomas. The reasons underlying this 
phenomenon may include the involvement of HR-HPV infection and more 
sophisticated treatment methods, such as IMRT. (137) In addition, as shown 
in the latest update of a meta-analysis, concomitant CT as a part of the 
treatment for HNSCC reduces the 5-year mortality by up to 6.5% (104).   
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T and N class have been regarded as the most important factors affecting the 
outcome of OPSCC (138-140). Stage, a derivative of T and N class reflecting 
the extent of disease, has also been shown to independently impact on the 
outcome (141, 142). More recently, survival analysis adjusted for HR-HPV 
status has suggested that in HR-HPV-negative OPSCC, stage (143) and N class 
(144), but not so clearly T class (143, 144), influence survival. Interestingly, in 
HR-HPV-positive OPSCC, only T class seems to be prognostic (143, 144). It is, 
however, well established that the UICC and AJCC 7th editions of the TNM 
staging (79, 80), which are not based on HR-HPV association, do not reflect 
patient survival as well as before the HPV-associated era (122).  
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It is widely established that patients with HR-HPV involvement have better 
survival in OPSCC (145, 146), and that HR-HPV status is currently the best 
marker in the prognostication of OPSCC (14, 23). A meta-analysis has shown 
  36 
that patients with HR-HPV-positive OPSCC have 28% lower five-year overall 
mortality, and a 49% higher disease-free survival rate (146). The better 
treatment response among HR-HPV-positive tumors is suggested to be due to 
better radiosensitivity (117, 147, 148). The treatment outcome of HR-HPV-
positive OPSCC, however, seems to be modality independent (16). Better 
outcome among HR-HPV-positive tumors may be associated with the absence 
of viral field cancerization, reducing the risk of locoregional recurrence and 
secondary primary tumors (149), and with enhanced immune surveillance and 
virus specific antitumor activity (31, 32). However, an aggressive 
neuroendocrine variant of HR-HPV-positive OPSCC with positivity for 
synaptophysin, chromogranin, and CD56 has also been recognized (69). 
 
HR-HPV status determination has some shortcomings in sensitivity, 
specificity, and accessibility. Tests that are based on the HR-HPV-DNA 
polymerase chain reaction (PCR) may be oversensitive and lack sufficient 
specificity. Therefore, the positivity may also indicate a non-transcriptional 
HR-HPV infection (150). Tests that are based on HR-HPV-DNA ISH may have 
insufficient sensitivity, while their specificity is good. ISH results are analyzed 
in the histological context, and if staining is only positive in tumor cells, the 
positivity can be regarded as a sign of transcriptional HR-HPV infection (151). 
HPV E6/E7-mRNA PCR may only detect transcriptionally active, relevant, 
HR-HPV infection, and it is therefore considered as the most reliable test for 
HR-HPV involvement (152). However, it usually requires fresh frozen tissue 
specimens. Protein p16 overexpression due to E7 binding on pRB can be 
detected with immunohistochemistry, a method available in routine 
laboratories. p16 overexpression (>70% of the tumor tissue stains strongly) 
can be used as a surrogate marker for HR-HPV with good sensitivity, but 
moderate specificity (153). Protocols that reliably identify tumor HR-HPV 
status, combine the strengths of p16 immunohistochemistry (IHC) and HR-
HPV detection. According to the method suggested by Smeets et al. (152), p16 
IHC is performed on all samples and p16 negatives are considered as HR-HPV 
negative. HR-HPV PCR is performed for the p16-positive samples, and only 
the samples that are positive for both p16 IHC and HR-HPV PCR are classified 
as HR-HPV positive. Furthermore, a combination of p16 IHC and HR-HPV 
ISH can be performed in a similar manner to improve the classification of 
samples as HR-HPV positive  (154).  
 
HR-HPV status may have an interaction with certain factors, such as T and N 
classification and stage, and thereby modify both their odds and prognostic 
significance (143, 144). However, the new AJCC 8 staging for OPSCC, which is 
based on the p16 status of the tumor, supposedly improves the prognostication 
of TNM (155). 
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Smoking (14) and heavy use of alcohol (15) may affect the outcome of OPSCC 
independently of HR-HPV status. One pack-year of smoking accounts for a 1% 
increase in the annual mortality risk (14). Similarly, heavy alcohol 
consumption causes a 2.6-fold increase in the mortality risk (15). The 
interaction between smoking and alcohol in the risk of developing pharyngeal 
cancer is well known, (156), but their potential synergistic effect on survival 
remains open. 
	 #! !"#!!"
 
For further classification of the prognosis in OPSCC, complementary markers 
to HR-HPV are required. Previously, an association has been suggested 
between a poor outcome and high expression of markers including HIF-a 
(157), c-met, Bcl-2 (158), Ki-67 (159), a combination of VEGF and EGFR (160), 
Cox-2 (161), nuclear survivin (162), MVP (163), phosphorylated 
serine/threonine protein kinase B (AKT) (164), heregulin mRNA, HER 3 (165), 
cytoplasmic Bmi-1 (166), and FHIT (167). In addition, loss of the 16q gene and 
the absence of 11q13 gene amplification have been shown to be associated with 
a good outcome (168). It is, however, noteworthy that validation of these 
suggested markers remains fairly limited in OPSCC research (169). 
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In 2010 Ang et al. reported that OPSCC patients can be divided in to three 
different groups with distinct outcomes according to HR-HPV status, smoking 
pack years, and T and N classes (14). Based on their results, they suggested 
that de-intensification of treatment for the HR-HPV-positive group with the 
best outcome is justified. As patients with HR-HPV-positive OPSCC are 
generally younger and have a higher probability of a more favorable treatment 
response and better survival, treatment de-intensification in order to 
minimize post-treatment adverse effects without increasing the risk of failures 
seems to be well justified (170). OPSCC treatment generally requires 
multimodality treatment with high doses of radiation, and these patients may 
experience several late toxicities such as xerostomia, swallowing difficulties 
and pain, and ototoxicity. New treatment strategies with treatment de-
escalation are therefore warranted (171). Several de-escalation studies are 
ongoing with an aim to evaluate the benefit of cetuximab instead of cisplatin, 
de-intensification of RT doses, induction CT before de-intensified RT doses, 
and less invasive surgery (170).  
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The locoregional control rate in HR-HPV-positive OPSCC is typically good, 
and the failures seem to predominately occur at distant sites (172). O’Sullivan 
et al. demonstrated that patients with HR-HPV-positive OPSCC and N2c 
classification treated with RT alone had a distant control rate of only 73%, 
while for those who received CRT, the corresponding figure was 92% (173). 
Therefore, they suggested that de-intensification from CT should be avoided 
in patients who are considered to be at high risk of developing distant 
metastasis (173). Most de-escalation studies use p16 overexpression in HPV 
status determination due to practical reasons, which has also been criticized 
(170). Patients who have p16-positive, but HPV-negative OPSCC tend to have 
survival rates resembling those of patients who have p16-negative and HR-
HPV-negative OPSCC (23). In fact, the tumors of the former group have 
genetically more similarities with HR-HPV-negative tumors than with HR-
HPV-positive tumors (174). 
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A total of 5% of all cancers worldwide are attributed to HPVs (175). The first 
prophylactic HR-HPV vaccine was approved for the prevention of cervical 
carcinoma in 2006 (176). Subsequently, vaccines preventing infections of 
more HPV types have been introduced, and vaccination has also been studied 
in the prevention of cancers arising from other sites than the cervix (176). 
Vaccines have been shown to be highly effective against HR-HPV and sequel 
anogenital precancerous lesions (177). As the most important HR-HPV types 
responsible for OPSCC are HPV-16 and HPV-18, it has been debated whether 
vaccine prevention of HR-HPV-associated OPSCC would be relevant (64). In 
the oropharynx, the detection of precancerous lesions using cytology has been 
shown to be unfeasible, possibly because the relevant tonsillar epithelium is 
difficult to sample (178). However, although the vaccination effect on 
precancerous lesions may be difficult to prove, vaccination has been shown to 
significantly reduce the prevalence of oral HR-HPV infections, possibly 
implying that vaccination may have a role in the prevention of OPSCC (179).   
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Innate immunity is in a key position in the initiation of the inflammatory 
response in a process mediated by toll-like receptors (TLRs), which are 
normally expressed by various immune cells and epithelial cells located near 
the host–environment boundary (180, 181). These receptors are activated by 
molecular patterns, such as proteins, RNA, or DNA strands, which can be 
either exogenous or endogenous. Exogenous patterns are called pathogen-
associated molecular patterns (PAMPs) (180, 181) and endogenous ones are 
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called danger-associated molecular patterns (DAMPs) (182, 183). TLRs belong 
into a family of 10 transmembrane receptor proteins, of which TLR 1, 2, 5, 6, 
and 10 have an extracellular receptor domain, and TLR 3, 4, 7, 8, and 9 have 
their receptor domain located inside an intracellular vesicle (184). 
Downstream of TLRs there are multiple cascades, the most important of which 
results in the activation of nuclear factor B (NF-B), which controls the 
transcription of proinflammatory cytokines, but also proteins participating in 
cell survival and proliferation (Figure 3). TLRs can also activate mitogen-
activated protein kinase and TRAF-3 mediated pathways (184). Under normal 
conditions, TLR activation maintains systemic homeostasis by defending the 
organism by triggering immunity towards harmful molecular structures. 
However, TLR activation may also result in inflammation becoming chronic, 
which may offer a favorable basis for cancer development (36). 
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The first observations indicating an association with TLRs and cancer were 
made without modern knowledge of immunology. In the 1890s, Dr. Coley 
showed that the administration of killed bacterial extracts resulted in 
antitumor activity (185). Another finding that nowadays is considered to be 
related to TLRs occurred earlier in the 1900th century, when Dr. Virchow 
noticed that cancer often developed into a site with chronic inflammation 
(186). Today, an association is known to exist between chronic inflammation 
and various types of cancer, such as Helicobacter pylori infection with gastric 
cancer (187), HPV with cervical cancer (188), ulcerative colitis and Crohn’s 
disease with colon cancer (189), and hepatitis infections with hepatocellular 
cancer (190).  
 
Many studies have shown that TLRs are overexpressed in premalignant and 
cancerous cells or tissues (191-194), indicating that TLRs play an important 
role in carcinogenesis and tumor progression. TLRs can modulate the 
immunity of the tumor microenvironment, increasing the levels of 
immunosuppressive agents such as vascular endothelial growth factor and 
transforming growth factor beta, and therefore increase angiogenesis and the 
odds of metastasis (195). In addition, TLRs can activate immunity by secreting 
nitric oxide synthase 2 and cyclooxygenase 2, which may cause tumor 
progression (191, 196).  Activation of TLRs can, however, also lead to the 
opposite result: tumor inhibition by activating the immunologic response 
towards cancer (197-200). 
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Figure 3. Activation of Nf-B following TLR activation. Intracellular 
Myd88 is recruited to activate Nf-B. In the case of TLR 1-2, TLR 2-6, and 
TLR 4 activation, bridging adapter MAL is recruited. TLR 3 activation is 
followed in a Myd88 independent manner using TRIF as an adapter. TLR 4 
activation may be followed by the Myd88 pathway where MAL is involved 
or the Myd88-independent pathway with adapter proteins TRIF and TRAM.  
(Modified and reprinted with the permission of Nature Publishing Group. 
(201)). 
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As the association of TLR expression and cancer development and progression 
has been well established, numerous cohort studies have shown the 
relationship between TLR expression and survival in various types of cancer 
(202-212). In addition, abundant studies on TLR signaling and its 
consequences in cancers have been published (213). The effect of TLR-
mediated cancer treatment can be caused by various processes. It may lead to 
apoptosis of tumor cells, increased vascular permeability and thus tumor 
regression, but also directly or indirectly recruit leukocytes and thus activate 
natural killer cells and T cells (214). The pursued anticancer activity of TLR 
agonists is thought to be a consequence of the activity of myeloid cells such as 
monocytes, macrophages, and dendritic cells (215). However, TLRs are also 
expressed on cancer cells, and many studies have pointed out their role in 
cancer progression or regression (213). Numerous clinical trials on TLR 
agonists are ongoing (215), and TLR agonists are currently used in the 
treatment of urinary bladder carcinoma (215, 216) and basal cell carcinoma of 
the skin (215, 217). 
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The first part of this study analyzed the treatment and outcome of OPSCC in 
two patient series, the first comprising all patients treated at the five Finnish 
university hospitals and the second focusing on the management of the neck 
in cN+ disease in patients treated at Helsinki University Hospital. The second 
part of this study examined the role of TLRs in OPSCC.  
 
The specific aims of this study were: 
1. To gather information on the given treatment, outcome, and prognostic 
factors in a multicenter cohort including all patients diagnosed and 
treated at the five Finnish university hospitals between 2000 and 2009. 
Special emphasis was given to the change in the treatment approach;  
2. To evaluate the management and outcome of the cN+ neck in OPSCC;  
3. To examine the expression of TLR 2, 3, 4, 5, 7, and 9 in HR-HPV-
positive and HR-HPV-negative OPSCC in vivo and in vitro; 
4. To study the prognostic influence of TLR 5, 7, and 9, and their 
association with clinical parameters in OPSCC in a patient series. 
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Study I covered all patients who were diagnosed and treated for OPSCC at the 
five Finnish university hospitals between January 1st, 2000 and December 31st, 
2009. A total of 674 patients were identified, and 600 of them received 
treatment with curative intent.  
 
At each university hospital, information was manually collected from hospital 
patient records regarding clinicopathological data, treatment, and outcome. 
Formalin-fixed paraffin blocks were collected from the archives of the 
Department of Pathology at each university hospital, and p16 IHC on 
formalin-fixed paraffin blocks was carried out retrospectively. The p16 status 
of the primary tumors was determined for the patients treated with curative 
intent, and of these, tumor tissue was available in 431 (71.8%) cases. The dates 
and causes of death were provided by Statistics Finland. Patients with 
subsequent follow-up, or treatment carried out at a central hospital according 
to the recommendation of the university hospital multidisciplinary tumor 
board were included. Treatment was classified as completed if the radiation 
dose in combination treatment (surgery + RT or CRT) was at least 45 Gy, and 
in definitive oncological treatment (RT or CRT) at least 60 Gy. If at least one 
cycle of CT was given, patients were considered to have received CRT. Of the 
patients who were treated with an intent to cure, 99% and 75% had a minimum 
follow-up of 3 and 5 years, respectively, or until death. 
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Study II included all 313 patients diagnosed and treated for OPSCC at Helsinki 
University Hospital between January 1st, 2000 and December 31st, 2009. These 
313 consecutive patients also represented the Helsinki University Hospital 
material in Study I. The study focused on 201 patients with regional metastasis 
(cN+) who were treated with curative intent. Of these, we further analyzed a 
subgroup of 169 patients who underwent treatment that was considered 
completed on the same grounds as in Study I, and who had a curative response 
(CR) for treatment and were disease free at three months after treatment 
completion. Combination treatment (surgery ± RT or CRT) was delivered to 
   43
107 patients and 62 patients received definitive oncological treatment (CRT or 
RT ± surgery). 
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Study III included a cohort (n=35) of OPSCC patients diagnosed at Helsinki 
University Hospital, as well as five OPSCC cell lines (UT-SCC 65, -69, -60A, -
60B, and -102) and one oral tongue cancer cell line (HSC-3). We aimed to 
evaluate TLR 2, 3, 4, 5, 7, and 9 expression, p16 status, and HR-HPV status in 
vivo and TLR 5 and 7 expression, p16 status, and HR-HPV status in vitro.  
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The population of study IV consisted of 331 patients, of whom 18 were 
excluded due to histology other than SCC or a subtype of SCC. The remaining 
313 OPSCC patients were the same patients as in Study II. Furthermore, 
patients were excluded with palliative intention of treatment (n = 44), 
concurrent HNSCC (n = 5), earlier-treated HNSCC (n = 11), and unavailability 
of tumor tissue (n = 51). Finally, a total of 202 patients were analyzed in this 
study. TLR 5, 7, and 9 expression and p16 status were immunohistochemically 
determined using the tissue microarray (TMA) method. HR-HPV status was 
determined using ISH.  
 
	 '5==?2750<9.<<.B.81577?8945=>904275=><B
 
For TMA blocks, we selected three different areas based on the invasion 
depth from slides stained with H&E. Six representative 1-mm core biopsies 
from marked areas of each tumor were placed in a paraffin block with a 
manual tissue microarrayer (Beecher Instruments, Silver Spring, MD, USA). 
Two similar blocks were produced from all samples.   
 
Four-micrometer-thick tissue slides were cut, deparaffinized in xylene, and 
rehydrated in a graded series of alcohol. Slides were treated in a PreTreatment 
module (Lab Vision Corp., UK Ltd, UK) in Tris-HCl buffer (pH 8.5). Blocking 
of endogenous peroxidase was carried out with 0.3% Dako REAL Peroxidase-
Blocking Solution. 
 
The antibodies used in immunostaining were: polyclonal rabbit anti-human 
TLR 2, 3, 4 (1:50, sc-10739, sc-10740, sc-10741), and 9 (1:100, sc-25468 Santa 
Cruz Biotechnology, USA), monoclonal mouse anti-human TLR 5 (1:200, 
IMG-664A Imgenex, USA), monoclonal rabbit anti-human TLR 7 (1:300, 
IMG-581A Imgenex, USA), and monoclonal mouse anti-human p16INK4a (9517 
CINtec Histology Kit, MTM laboratories, Germany).  
Epitope retrieval was carried out with Tris-HCl for TLR 2, 4, and 7, and Tris-
EDTA for TLR 3, 5, and 9. Dako REAL DAB+ Chromogen was used for staining 
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visualization. Between each step, PBS-0.04%-Tween20 was used for washing 
the slides. Counterstaining was performed with Meyer’s hematoxylin and 
mounting with Aquamount, (BDH, Poole, UK). Antibody incubation was 
carried out with the Dako REAL Antibody Diluent S2022. The incubation time 
was 60 minutes for TLR antibodies and 30 minutes for p16INK4a antibodies. For 
each antibody, a positive control was used. Incubation of negative controls was 
performed in diluent lacking the primary antibody. 
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UT-SCC cells were cultured at 37°C in DMEM medium with 4.5 g/l glucose, 
supplemented with 10% fetal calf serum (FCS), HEPES, non-essential amino 
acids, glutamine, and penicillin and streptomycin (Sigma Aldrich). The HSC-
3 cells were cultured in an equivalent amount of DMEM medium with 4.5 g/l 
glucose and Ham’s F12 Nutrient mixture supplemented with 10% FCS, 
penicillin, streptomycin, sodium pyruvate, and hydrocortisone. Nonidet P-40 
(NP-40) lysis buffer (1% NP-40, 20 mM HEPES, pH 7.5, 150 mM NaCl) was 
used in the lysing of cells supplemented with 50 mM NaF, 1 mM Na3VO4 and 
1 x Complete Proteinase Inhibitor Cocktail (Roche, Basel, Switzerland) at 4°C 
for 30 min. Centrifugation was used for the removal of detergent-insoluble 
material (16 000 x g at 4 °C for 15 min).  
 
SDS-PAGE (10%) served in separation, PVDF-FL membranes (Millipore, 
Billerica, MA) served as transfer membrane, and Odyssey blocking buffer (LI-
COR, Lincoln, NE) diluted 1:1 with PBS served in blocking of equivalent 
amounts of total cell lysates (50 μg). Membranes were incubated with TLR 5 
and 7 antibodies as described above, mouse anti-actin (Sigma) followed by 
Alexa Fluor 680 (Invitrogen) and IRDye 800 (LI-COR Biosciences) anti-
mouse or anti-rabbit secondary antibodies. The dilution of 1:200 was used for 
TLR 5 and 7 antibodies. The Odyssey Infrared Imager (LI-COR) was used in 
signal detection and Odyssey software in subsequent quantification. 
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In Study III, we detected HPV-DNA by PCR. DNA was extracted from from the 
paraffin embedded formalin-fixed sections and amplified with primer sets 1 
and 2 from the Multiplex HPV Genotyping Kit® (DiaMex GmbH, Germany). 
A negative control, which contained no genomic DNA, was used to confirm the 
absence of contamination. Genotyping of HPV was performed with a Multiplex 
HPV Genotyping Kit® (DiaMex GmbH, Germany) detecting the following 24 
LR- and HR-HPV-genotypes: LR-HPV6, 11, 42, 43, 44, and 70; and HR-
HPV16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82 (218). 
A Luminex LX-100 analyzer (Bio-Plex 200 System, Bio-Rad Laboratories, 
Hercules, USA) served in the analysis of the labeled hybrids.  
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Pellets of UT-SCC-65, -69, -60A, -60B, and -102 cells were formed, and they 
were analyzed at Quattromed HTI Laboratory, Tartu, Estonia. HPV DNA 
amplification was performed targeting the E6/E7 region of the viral genome 
by PCR. Products were detected using a laboratory-developed Luminex-based 
assay (Quattromed).  
 
In Study IV, we used the Ventana Inform HR-HPV in situ hybridization assay 
with a high-risk HPV probe and iVIEW Blue detection kit and the Benchmark 
XT series stainer (Tuscon, Arizona, USA). Tissues sectioned at 5 μm thickness 
were used. Extended Ventana cell conditioning solution (CC2) was used and 
pretreatment was carried out with an incubation time of 32 minutes with ISH 
protease 3. In the assay, the following HR-HPV subtypes have been 
demonstrated to be detected: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66.  
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Statistical analysis was performed in SPSS Version 20.0 (SPSS, Inc., Chicago, 
IL, USA).  The chi-square test with asymptotic and exact P values and the 
Mann-Whitney U-test were used in calculating the statistical significance of 
differences between categorical variables. The differences in continuous 
variables between independent groups were evaluated using the independent-
samples T-test and the Mann-Whitney U-test. The normality of the 
distribution was inspected from a histogram, and in uncertain cases, the 
Shapiro-Wilk test served in the evaluating the normality of the distribution. 
The Kaplan-Meier estimate with the log-rank test and Cox proportional 
hazards model were used to analyze the survival of patients according to 
clinicopathological factors and biomarkers. The endpoints were as follows: 
overall survival (OS), disease-specific survival (DSS), disease-free survival 
(DFS), and recurrence-free survival (RFS). In order to minimize follow-up 
bias, we adjusted the follow-up time in the analysis to a maximum of five years. 
The follow-up time was the period between the last day of treatment and the 
end of follow-up or death of any cause in OS, and death with disease in DSS. 
The DFS time was calculated from the last treatment day to the detection of 
OPSCC recurrence either at the primary tumor site, in regional lymph nodes, 
or both, or at distant sites. In addition to recurrence, death of any cause was 
considered as an event. The RFS time was similarly calculated from the last 
treatment day to the detection of OPSCC recurrence either at the primary 
tumor site, in regional lymph nodes, or both or, at distant sites. In order to 
adequately present the recurrence rate of locoregional and distant RFS, we 
only considered OPSCC recurrence as an event. A two-tailed P-value of less 
than 0.05 was considered statistically significant. 
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This study obtained institutional study permission and approval from the local 
ethics committee (record number: 179/13/03/02/2013). In Study I, all 
university hospitals obtained their own institutional study permission. 
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In total, 674 patients were diagnosed and treated for OPSCC at the five Finnish 
university hospitals over the ten-year period from 2000–2009. Most of the 
patients (n = 313, 46.4%) were from the Helsinki University Hospital area. Of 
these patients, 600 received treatment with curative intent, and their clinical 
characteristics are presented in Table 3. The mean age of the patients was 58.4 
years (range 26.5–90.8 years). Patients with a p16-positive tumor were 
younger, with a mean age of 56.8 years, than those carrying a p16-negative 
tumor, with a mean age of 60.6 years. The lateral wall of the OP was the most 
common subsite of primary tumors, and p16 positivity was clearly associated 
with this subsite. In the anterior wall of the OP, the proportion of p16-positive 
and -negative tumors was almost equal. Superior-wall tumors were mostly p16 
negative, and posterior-wall tumors rarely occurred. p16-positive tumors were 
somewhat more often classified as T1-2 (66.3%) than p16-negative tumors 
(54.2%), but the classification of regional lymph nodes in p16-positive disease 
was higher (cN+ 84.9%) than in p16-negative diseases (cN+ 68.7%). 
Therefore, the stage was generally higher in the p16-positive group (III-IV 
90.1%) than in the p16-negative group (III–IV 76.5%). Smoking habits also 
differed between these groups, as among patients with a p16-negative tumor, 
only 3.5% were never-smokers, while the corresponding proportion was 37.4% 
in p16-positive group. Most tumors that were p16 negative were well or 
moderately differentiated (grade 1–2, 67.3%), while 61.6% of p16-positive 
tumors were poorly differentiated. 
 
Of the 600 patients with curative treatment intent, 564 were able to receive 
the complete treatment. Of this patient group, 270 (47.9%) received primary 
surgery. ND was performed for 243 (92.4%) at the time of primary surgery. 
Postoperative oncological treatment was given to 248 (91.9%) patients. 
Oncological treatment as curative first-line treatment was given to 294 (52.1%) 
patients. Of these, 249 (84.7%) received CRT and 45 (15.3%) RT. Three 
patients received RT with adjuvant or neoadjuvant CT. Surgery after definitive 
CRT and RT was performed for 46 and 8 patients, respectively. 
 
The 3-year OS, DSS, and DFS in all patients treated with curative intent was 
70.2%, 76,7%, and 66.0%, respectively. The 3-year DSS in patients with a p16-
positive tumor was 88.1% and with a p16-negative tumor 63.2%. The 
treatment received and the 3-year outcome for the patients treated with 
curative intent for lateral-wall and anterior-wall tumors are presented in Table 
4.  
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According to the univariate analysis, patients who underwent primary surgery 
and received postoperative oncological treatment for lateral-wall OPSCC had 
better DSS than those who received definitive oncological treatment. Patients 
with anterior-wall OPSCC had better DSS if they received definitive CRT 
instead of other treatment. 
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In patients with p16-positive OPSCC, the 3-year DSS rate for those patients 
who underwent definitive CRT was 86.3%, compared with 93.4% in those 
patients who underwent upfront surgery followed by adjuvant treatment (p = 
0.077). The corresponding figures for p16-negative OPSCC were 67.7% and 
68.9% (p = 0.621). Among currently smoking patients, the 3-year DSS was 
lower in patients treated with definitive CRT (62.9%) compared with those 
who underwent upfront surgery followed by adjuvant treatment (75.8%), but 
the difference was not statistically significant (p = 0.066). More importantly, 
among smokers with a p16-positive primary tumor, the corresponding figures 
were (72.7%) and (91.6%) (p = 0.028). Among smokers with a p16-positive 
primary tumor, there was no association between the treatment method and 
DSS. (Jouhi, L et al., unpublished results) 
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Multivariate analysis of patients treated with curative intent was performed 
separately for lateral-wall and anterior-wall OPSCC, because the tumor site 
had a statistically significant interaction with treatment (p = 0.013), with RT 
modality (p = 0.001), and with N class (p = 0.037) (Table 5). Factors associated 
with disease mortality in lateral-wall disease were the presence of cervical 
metastasis, p16 negativity, and male sex. Among patients with anterior-wall 
disease, p16 negativity, male sex, classes T3-T4, and 3D conformal RT were 
factors associated with a higher likelihood of disease mortality.  
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In Study II, the incidence of RRs was evaluated in 169 patients with complete 
curative treatment for cN+ OPSCC and a curative response after three months 
from treatment completion. Of these, 107 patients underwent primarily 
surgical treatment and 62 received definitive oncological treatment. 
Altogether, seven RRs occurred: five in the primarily surgically treated group 
and two in the definitive oncological treatment group. The incidence of RR was 
low in both groups (4.7% and 3.2%), and despite the treatment change towards 
a more oncological approach during the study period, the incidence of RRs 
remained unchanged. Patients with RR are presented in Table 6. All patients 
who developed RR had clinical N class of N2b or higher. Six of the seven 
patients with RR had a p16-positive primary tumor. Regional recurrence 
developed in the contralateral side of the neck in five of the seven patients. 
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Tissue samples were collected from the most recent OPSCC cases (n = 35) for 
which p16 status was available. Twenty-one of the samples were positive for 
p16 IHC and 14 were negative. HR-HPV positivity was detected in 18 samples, 
while 17 were HR-HPV negative. The sensitivity and specificity of p16 for HR-
HPV detection was 94.4% and 76.5%, respectively. All the investigated TLRs 
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(TLR 2, 3, 4, 5, 7, and 9) were found to be expressed in OPSCC, and TLRs 2, 3, 
4, 7, and 9 were expressed in tumor-infiltrating lymphocytes. TLR 7 and TLR 
9 expression patterns depended on the tumor HPV status: TLR 7 expression 
was high and TLR 9 expression low in HR-HPV-positive OPSCC. The 
expression patterns of TLR 5 and 7 depended on the tumor p16 status: TLR 5 
expression was low and TLR 7 expression high in p16-positive OPSCC. (Table 
7). 
 
 
 
 
 
Five OPSCC cell lines (UT-SCC 60A, 60B, 65, 69, and 102) were examined for 
p16 status, HR-HPV status, and TLR 5 and 7 expressions. The oral SCC cell 
line HSC-3, known to be HR-HPV negative, was studied for p16 status and 
TLR 5 and 7 expressions.  All five OPSCC cell lines were HR-HPV-positive, but 
only one, UT-SCC 69, was p16 positive, whereas the rest (UT-SCC 60A, 60B, 
65, 69, 102, and HSC-3) were p16 negative. The cell line UT-SCC 69 expressed 
less TLR 5 and more TLR 7 compared with the p16-negative OPSCC cell lines. 
In addition, UT-SCC 69 expressed less TLR 5 than HSC-3, although the 
expression levels of TLR 7 did not differ significantly. 
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Altogether, 202 patients receiving treatment with curative intent for first-
primary OPSCC had primary tumor samples available for TLR 5, TLR 7, TLR 
9, and p16 expression and HPV status determination. Baseline 
clinicopathological data, as well as TLR 5 and 7 expressions in relation to HR-
HPV status and p16 status are provided in Table 8. Compared with HR-HPV-
negative tumors, HR-HPV-positive tumors expressed lower levels of TLR 5 
and TLR 9 and higher levels of TLR 7. 
 
High TLR 5 expression and low TLR 7 expression were associated with poor 
DSS (Figure 3). In the subgroup of HPV-positive tumors, patients with high  
TLR 5 expression and low TLR 7 expression had poor DSS, but among patients 
with HPV-negative OPSCC, the expression of these TLRs had no impact on 
DSS. In the Cox proportional hazards model, we adjusted the TLR 5 and 7 
expressions for sex, T class, N class, and HR-HPV (Table 9). HPV status had a 
statistically significant interaction with TLR 7 expression (p = 0.027), leading 
to stratification of multivariate analysis according to HR-HPV status. Among 
patients with HPV-positive tumors, high TLR 5 expression and low TLR 7 
expression presented as independent factors for poor DSS. In the HR-HPV-
negative subgroup, males and patients with advanced regional metastasis 
(N2a-N3) had significantly increased risk of disease mortality. 
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Figure 3. Disease-specific survival (DSS) curves according to TLR 5 and 7 
expression in OPSCC, and also separately for HR-HPV-positive and HR-
HPV-negative OPSCC. A: TLR 5 expression in OPSCC. High expression is 
associated with poor DSS. B: TLR 7 expression in OPSCC. High expression is 
associated with good DSS. C: TLR 5 expression in HR-HPV-positive OPSCC. 
High expression is associated with poor DSS, whereas low expression is 
associated with good DSS. D: TLR 5 expression in HR-HPV-negative OPSCC. 
No impact on DSS. E: TLR 7 expression in HR-HPV-positive OPSCC. High 
expression is associated with good DSS, whereas low expression is associated 
with poor DSS. F: TLR 7 expression in HR-HPV-negative OPSCC. No impact 
on DSS. 
Reproduced with the permission of Springer. 
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The OP is currently the most important subsite for HNSCC research, because 
the incidence of OPSCC has rapidly increased. The disease has now been 
categorized into two distinct entities according to the p16 status. In addition, 
the treatment paradigm has changed towards a more oncological approach. 
Patients with HR-HPV-positive tumors have markedly better survival, but due 
to the increased incidence, half of all OPSCC recurrences develop in patients 
with a HR-HPV-positive tumor (17). Furthermore, the pattern of recurrences 
is different: The rate of locoregional recurrence in HR-HPV-negative OPSCC 
is higher than in HR-HPV-positive OPSCC, but the rate of distant recurrence 
does not differ significantly between the two (14, 172). Reliable information 
regarding the optimal treatment for OPSCC remains limited, and differences 
between national OPSCC treatment guidelines possibly reflect this fact. 
Advances in the survival stratification for HR-HPV-positive and HR-HPV-
negative OPSCC, which may be offered by the new UICC and AJCC 8th edition 
(24, 25), might benefit the treatment selection. It is to be expected that the 
treatment for these two entities will become different. This study evaluated the 
OPSCC outcome in Finland, treatment of the cN+ neck, as well as the 
expression and prognostic value of TLRs in OPSCC. 
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This study described the treatment provided and factors influencing the 
outcome in a nationwide framework over a 10-year period. The incidence of 
OPSCC in Finland has increased, and this trend is likely to be related to the 
increase in p16-positive OPSCC cases.  
 
Among patients treated at Helsinki University Hospital, 18% had undergone 
tonsillectomy as a diagnostic procedure. Sometimes, tonsillectomy had 
resulted in clear margins. The intention in these cases was primarily a 
diagnostic procedure, and we therefore classified tonsillectomy as a biopsy in 
our study. Interestingly, in 19% of our patients, the tumor was classified as 
CUP before the diagnosis of OPSCC. Of these patients, 78% had a p16-positive 
primary tumor. (Jouhi, L et al., unpublished results) 
 
This study also demonstrated that treatment has changed in Finland as 
compared with a previous Finnish nationwide retrospective study including all 
patients diagnosed and treated for OPSCC at the same institutions during the 
years 1995–1999 (121). In the late 1990s, upfront surgery was the mainstay for 
treatment, as 85% of all patients underwent primary surgery (121), whereas 
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the corresponding figure was 49% among patients treated with curative intent 
in the present series. A similar paradigmatic change to that occurring in 
Finland has also been reported from other countries (28, 122). Definitive 
oncological treatment has been suggested as the first-line treatment in 
Denmark (30) and Sweden (29), although in the United Kingdom (20) and in 
the US (22), for instance, the national protocol does not similarly emphasize 
the role of non-surgical treatment. In our series, the treatment protocol 
seemed to function well, as 94% of the patients treated with curative intent 
were able to complete their treatment. 
 
The treatment outcome has also undergone changes in Finland. Although the 
five-year DSS remained fairly similar between 1995–1999 and 2000–2009 
(73% and 75%) in lateral-wall disease, the corresponding figures in anterior-
wall disease were 47% and 65%. The positivity of p16 in anterior-wall tumors 
increased from 38% in 2000–2004 to 59% in 2005–2009.  The factors 
associated with good DSS among patients with anterior-wall OPSCC were p16 
positivity, female sex, lower T class (T1-T2), and IMRT. In lateral-wall OPSCC, 
the treatment outcome remained similar. One explanation for this 
phenomenon could be the fact that the rate of p16-positive tumors in that site 
increased only slightly during the study period, from 64% to 71%. The disease 
mortality in lateral-wall OPSCC was influenced by the presence of regional 
metastasis, p16, and sex. Patients treated with definitive CRT ± salvage surgery 
compared with those who underwent primary surgery + (C)RT had a HR of 
1.8, but the finding remained non-significant (p = 0.073). The observation was 
significant in the model without backward elimination, however.  
 
According to the results of this study the role of surgery in the management of 
tonsillar disease remains open. A prospective randomized controlled study is 
warranted to evaluate the treatment of tonsillar disease. It has been suggested 
that even non-radical surgery may improve survival among tonsillar SCC 
patients (219, 220). In base of tongue SCC, the treatment modality did not 
have any effect on survival in multivariate analysis. However, surgical 
methods such as TORS may benefit patients from a functional viewpoint: if 
primary tumors are resected, patients may require less intensive postoperative 
oncological therapy (76, 120). In our material, 87 patients had a T1-T2 
classified anterior-wall tumor, of whom 36% underwent upfront surgery, 
typically requiring tissue transfers. These surgeries probably caused 
significant morbidity. TORS could especially benefit this patient group, but 
requires further study. Interestingly, according to our results, patients who 
underwent primary surgery did not benefit from clear surgical margins. Free 
margins are generally considered important in HNSCC treatment, as the 
margin status may impact on the outcome (221). Margins are, however, also 
important in HR-HPV-positive OPSCC: It has been suggested that in HPV-
positive, but not in HR-HPV-negative OPSCC, positive margins would 
independently increase overall mortality (222).  
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Our data do not support the findings of Wang et al. (18) and Seikaly et al. (19), 
who reported that patients with p16-negative OPSCC had significantly worse 
survival if they were treated with definitive oncological treatment instead of 
upfront surgery followed by adjuvant therapy. Furthermore, Seikaly et al. (19) 
concluded that among smokers carrying either a p16-positive or a p16-negative 
tumor, higher survival rates would be achieved after upfront surgery than after 
definitive CRT. In our material, neither of these main treatment modalities 
appeared to be superior among patients with p16-negative OPSCC. However, 
among smokers with p16-positive OPSCC, upfront surgery followed by 
adjuvant treatment resulted in higher DSS rates than definitive CRT. 
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In the second study our objective was to analyze the treatment of the neck in 
OPSCC. We focused on cN+ disease only, whereas the treatment of cN0 
disease was not analyzed in our study. As the treatment paradigm has changed 
towards a more oncological approach, and surgery is principally adopted for 
salvage purposes the relative rate of ND has also decreased. During our study 
period at the Helsinki University Hospital, organ-preserving treatment was 
provided to patients at an increasing rate, although upfront surgery did not 
seem to decrease. We did not detect any trend towards an increased 
occurrence of RR, although organ preservation was pursued more often. Of the 
patients who underwent primary surgery, 4.7% developed a RR, and of those 
who underwent definitive oncological treatment, 3.2% developed RR. 
Therefore, a “scan and wait” policy may benefit patients and reduce treatment-
related morbidity. The low rate of RRs after definitive oncological treatment 
(1.2% - 5%) has previously been reported (223-225). However, the rate of RRs 
has also been shown to be low (2%) after upfront surgery (226). Sakashita et 
al. investigated the benefit of upfront ND in cN+ OPSCC (227). Their study 
showed no regional control difference between the patient group that was 
treated with the primarily oncological treatment and the group that was 
treated with upfront ND.  
 
RR constitutes a significant cause of death in OPSCC. According to a study by 
Viani et al., only 19% of patients were alive at 5 years after the detection of RR, 
while the corresponding figure was 31% after local recurrence (228). Similarly, 
Röösli et al. (229) reported lower survival rates after surgical salvage for 
regional recurrence than for local recurrence. It is noteworthy that in their 
series, most patients with a local recurrence did not undergo salvage surgery, 
possibly reflecting limited resectability. Likewise, in our material, five-year 
DSS among patients with isolated RR was 25.7%. To compare, in oral SCC, 
according to a study by Ebrahimi et al., in oral SCC, only 53% of patients who 
developed RR died of disease (230). Likewise, Ord et al. showed that the 3-
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year OS after salvage surgery for RR in oral SCC was 50%. The outcome after 
salvage surgery in oral SCC appears to be impaired if ND has been performed 
prior to RR (231, 232). The pattern of recurrence in HR-HPV-positive OPSCC 
is different compared with HR-HPV-negative OPSCC: the rate of distant 
recurrences does not differ significantly between HR-HPV-positive and HR-
HPV-negative OPSCC, but in HR-HPV-positive OPSCC, unlike in HR-HPV-
negative OPSCC (172), locoregional recurrences are sparse, a phenomenon 
seen also in our nationwide cohort.  
 
In our material, five out of the seven RRs occurred on the contralateral side of 
the neck. Notably, two of these occurred in patients with an ipsilateral tumor 
of the tonsil. Seikaly et al. (19) observed that contralateral neck disease is 
relatively common in OPSCC, and it is not related to the site of the primary 
tumor, but rather to T class and N class, as among patients with a T4 tumor or 
N2a+ disease, the risk of contralateral disease was increased. In their study, 
contralateral RRs occurred at a rate of 2% at five years (82). The corresponding 
figure in our study was 3%. In our study, only one patient who developed a RR 
had a T4 classified primary tumor, but all RRs occurred in patients having an 
N class of cN2b or higher. 
 '+#%&&"!#''%!&"'"%#'"%&
%'*!%#)#"&')!%#)!')
"%"#%,!%!" &'(,
 
The third study evaluated the expression patterns of TLR 2, 3, 4, 5, 7, and 9 in 
OPSCC groups stratified by HR-HPV status and p16 expression. The 
expression of TLRs has been observed in a number of other HNSCCs (202, 
206, 212, 233-236), but in the OP their expression and relationship with HR-
HPV has remained unknown. TLRs have also been reported to have altered 
expression in carcinogenesis and carcinoma of cervix uteri (34, 35, 237). It has 
been shown that the expression patterns of TLRs differ between clearing and 
persisting HR-HPV infection of the cervical mucosa, possibly reflecting 
differences in the immune response between these events (33). In our 
material, TLR 5 expression was lower and TLR 7 expression higher in p16-
positive OPSCC. Furthermore, TLR 7 expression was higher and TLR 9 
expression lower in HPV-positive OPSCC. Kauppila et al. (202) studied TLR 5 
expression in the oral epithelium and in oral tongue squamous cell carcinoma 
(OTSCC), and observed that TLR 5 was more often overexpressed in cancerous 
tissue compared to normal oral epithelium. In our study, TLR 5 was 
significantly more commonly expressed in HR-HPV-negative and p16-
negative OPSCC compared with cancer-free tonsil epithelium.  However, no 
significant difference in TLR 5 expression patterns existed between HR-HPV-
positive or p16-positive OPSCC and cancer-free tissue. As it is well known that 
the importance of HR-HPV is minor in oral carcinoma (238), our results 
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suggest that OTSCC and HR-HPV-negative or p16-negative OPSCC share a 
similar TLR 5 expression profile. On the contrary, HR-HPV-positive and p16-
positive OPSCC had a TLR 5 expression pattern closer to normal epithelium 
than to HR-HPV-negative OPSCC or OTSCC. This finding possibly reflects the 
comprehensive differences between HR-HPV-positive and HR-HPV-negative 
OPSCC (59, 60). However, TLR 7 overexpression has been reported in oral 
SCC (206), suggesting that in terms of TLR 7 expression HPV-negative OPSCC 
and oral SCC differ. A study by Hasan et al. demonstrated that TLR 9 
expression is downregulated in HR-HPV-positive cervical carcinoma (35). In 
line with this finding, our results showed that HR-HPV-positive OPSCC had 
lower TLR 9 expression than its virus-negative counterparts. In the latest 
WHO atlas of head and neck tumors, p16-positive and p16-negative tumors 
are classified as different entities (69), which is in line with our TLR results. 
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The fourth study determined the expression of TLR 5, 7, and 9 in a patient 
series covering all patients diagnosed and treated at Helsinki University 
Hospital over a ten-year period. The results concerning TLR 5, 7, and 9 
expression in OPSCC stratified by HR-HPV and p16 status were similar to the 
previous study (Study III): the expression of these TLRs differed significantly 
between these two groups. In addition, TLR 5, 7, and 9 expressions were 
significantly associated with several patient or disease-related factors, most of 
which are also associated with HR-HPV status (6, 12, 14, 15, 239). Notably, 
high TLR 5 expression and low TLR 7 expression were associated with poor 
DSS. The patient cohort was analyzed separately for patients with a HR-HPV-
positive and a HR-HPV-negative tumor, and these TLRs were only prognostic 
in the HR-HPV-positive subgroup.  
 
An association between high TLR 5 expression and a poor prognosis in OTSCC 
has been reported (202), although contrary findings have also been presented 
(212). In addition, OSCC patients with high TLR 7 tumor expression have been 
shown to have a poor prognosis (206). In HR-HPV-negative OPSCC we did 
not observe any prognostic role of TLR 5 and 7, as suggested in OTSCC and 
OSCC.  
 
Several attempts have been made to clarify the role of TLR 5 and 7 in various 
types of cancer. In gastric cancer and salivary gland adenocarcinoma, tumor 
progression has been shown to be associated with TLR 5 activation (240, 241). 
However, TLR 5 activation did not cause tumor progression in OSCC (242). 
TLR 5 activation with a synthetic agonist, CBLB502, mediated 
radioprotectivity in tissues adjacent to the tumor, but not in the tumor itself 
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(243).  The authors speculated that the radioprotectivity occurred due to Nf-
B-mediated antiapoptotic activity. According to their speculation, tumor 
tissues were not desensitized because of the constitutive Nf-B activity in 
cancer (244) or inhibition of TLR 5 downstream signaling due to the potential 
activation of PIK3 (245). PIK3 may in fact act as a negative regulator of TLR-
mediated signals influencing inflammatory responses, cell proliferation and 
survival mediated by the Nf-B pathway (246). PIK3 activation is reported to 
promote radioresistance (247) and correspondingly inhibition of its 
downstream protein, AKT, is reported to promote radiosensitivity (248, 249). 
On the other hand, negativity of PTEN, a regulator of PIK3, combined with 
PIK3CA mutation may increase radiosensitivity in breast cancer (250). 
PIK3CA-activating mutations are relatively common in HR-HPV-positive 
OPSCC (66-68). (251) PIK3CA mutation has not reported to be prognostic in 
OPSCC (68) or in other HNSCCs (251). Amplification of PIK3 has been shown 
to be related to poor DFS in HNSCC patients with no lymph node metastasis 
(252). However, Sewell et al. reported that in their HR-HPV-positive cohort 
all disease deaths occurred among those patients, who did not have a PIK3CA 
mutation (66). In esophageal SCC PIK3CA-activating mutation has been 
shown to be related to a good prognosis (253). Therefore, the role of PIK3 
appears to be contradictory in cancer. However, the association of the 
radiation response and TLR 5 expression remains speculative in HR-HPV-
positive OPSCC. The association of TLR 5 and PIK3CA mutation, and their 
functions, especially regarding the radiation response, should be further 
examined in OPSCC. 
 
Activation of TLR 7 has promoted treatment resistance in adenocarcinoma 
and SCC of the lung, possibly via an Nf-B mediated pathway and upregulation 
of antiapoptotic protein Bcl-2 (254, 255). Activation of TLR 7 in OSCC, 
however, induced tumor apoptosis and necrosis (256), and in breast cancer 
sensitized cancer cells to RT (257). Based on our results we may only 
hypothesize, whether the radiosensitivity of HR-HPV-positive tumors could 
be associated with TLR 7 overexpression.  
 
Numerous potential prognostic or predictive molecular markers have been 
studied in HNSCC (258). Even though HR-HPV is well validated as a 
prognostic marker in OPSCC, the predictive value of HR-HPV requires further 
investigation (20-22). Therefore, further molecular marker studies in HNSCC 
are needed to find the biomarkers that could be used in daily practice. 
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Study I comprised a large cohort of consecutive patients treated over a 10-year 
period at the five Finnish University Hospitals, in which HNSCC treatment is 
mainly centralized. Unfortunately, we were unavailable to determine the 
  64 
coverage of our patient series in comparison with the numbers provided by the 
Finnish Cancer Registry (FCR), because in its reports the pharynx has not been 
divided into its sublocations. According to the FCR, 1286 new pharyngeal 
cancer cases occurred during the time frame of this study. This number also 
includes pharyngeal carcinomas originating outside the OP, complicating 
head-to-head comparison. Thus, it remains speculative how large proportion 
of Finnish OPSCC patients were treated at the University Hospitals. However, 
our report offers comprehensive information on the treatment or OPSCC and 
the outcome after curative intent. More importantly, nearly all treatment for 
malignancies is performed at public hospitals in Finland, and treatment 
selection is not affected by factors such as income or insurance. In addition, 
the compliance with treatment is high and patient follow-up is comprehensive. 
The retrospective nature of our study caused limitations in data, especially 
concerning details on smoking and alcohol abuse. A fact that improves the 
feasibility of our results concerning the treatment outcome is that the p16 
status had no effect on the treatment selection, but in contrast, a long inclusion 
period may have caused bias because treatment modalities have changed 
during the years. Our study would also have improved if we had been able to 
adjust for comorbidities and performance in the multivariate survival analysis. 
Therefore, we were not able to eliminate the impact of these factors in the 
treatment decision. In addition, our multivariate analysis suffered from 
moderate correlations between the investigated parameters, possibly reducing 
their explanatory power. 
 
Study II included patients who were treated at Helsinki University Hospital 
and had N+ disease. As in Study I, treatment changed during the time frame, 
and the p16 status did not impact on treatment selection. However, we were 
unable to compare either the rate of complete treatment response or the 
occurrence of RR between the two treatment groups, as other factors, such as 
T and N classes and comorbidities, may have influenced treatment selection, 
and therefore biased the results. Nevertheless, we were able to show that the 
occurrence of RR was low, and while the treatment changed towards a more 
oncological approach, the incidence of RR did not increase. 
 
Study III included a relatively small cohort of tumor samples, and it was not 
uniform regarding clinicopathological factors. No association was detected 
between TLR 5 expression and HPV status, or between TLR 9 expression and 
p16 status, possibly due to the small sample size. These associations were, 
however, observed in a larger cohort in Study IV. Although p16 status and HPV 
status were associated with each other in vivo, the results of the cell culture 
study revealed discordance between these factors. We may only speculate, 
whether the HR-HPV positivity in our p16-negative OPSCC cell lines reflects 
the actual involvement of HR-HPV in the disease etiology of these cell lines. 
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In Study IV we were able to demonstrate that TLR 5 and TLR 7 expression 
associated with DSS in HR-HPV-positive OPSCC. An important weakness in 
this study concerns the number of events. Although the cohort had 202 
patients and the number of HR-HPV-positive cases was 105 (52.0%), the 
number of events in DSS analysis of this subgroup of interest was only 18 
(17.1%), whereas it was 31 (32%) in the HR-HPV-negative group. A good 
prognosis in HPV-positive OPSCC is well-known from the literature, but it 
restricted the reliability of survival analyses, especially because the number of 
patients having adverse TLR expression was low. As a result of this, the 95% 
confidence intervals were broad for adverse TLR 5 and TLR 7 expression HRs. 
More importantly, the multivariate analysis stratified according to p16 status 
did not show a statistically significant HR for adverse TLR 7 expression, 
possibly due to the same reason. Therefore, robust conclusions cannot be 
drawn concerning TLR 5 and TLR 7 expression and survival, and further 
studies are needed for possible validation of these results. In addition, 
multivariate analysis suffered from a lack of knowledge of comorbidities and 
performance. The analyses included two patients whose tissue samples were 
obtained from salvage surgical specimens, in which the TLR expression before 
RT cannot be evaluated. 
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The treatment paradigm of OPSCC is undergoing continuous change, and the 
rate of surgery may again be increasing. Therefore, treatment and outcome 
details of OPSCC patients treated after 2009 would call for further evaluation 
in the future. A prospective database incorporated in patient records would 
markedly ease the evaluation of patient cohorts. Currently, p16 staining is 
routinely performed in Finland, but HR-HPV detection is not. A uniform 
method for HR-HPV status determination in clinical practice remains to be 
determined. Future research is also needed to find out whether the incidence 
of p16-positive OPSCC is still increasing. TORS was introduced for head and 
neck cancer treatment at the Helsinki University Hospital in 2014. The role of 
TORS in OPSCC treatment needs further evaluation.  
 
RR constitutes a significant cause of mortality in OPSCC. The extent of neck 
treatment must take into account both treatment failures and the functional 
outcome. At our institute, the relative rate of ND decreased, but the rate of RR 
did not change. Definitive oncological treatment is more often being delivered 
and evaluation of the treatment response relies on PET-CT, which is 
performed at three months after treatment completion. However, this imaging 
procedure produces false-positive findings, which may predispose patients to 
unnecessary surgery. Further studies on treatment response imaging are 
therefore needed. The use of BNCT will be re-initiated at the Helsinki 
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University Hospital, and its role in the treatment of recurrent HNSCC will 
require further studies. 
 
We were able to show that TLR 5 and TLR 7 may affect the prognosis of HR-
HPV-positive OPSCC patients. These findings were obtained from small 
cohorts, and they will need further validation in larger cohorts. We have no 
biological explanation for this phenomenon. We are currently evaluating 
whether the downstream cascades of TLRs differ between p16-positive and 
p16-negative OPSCC in vitro. Furthermore, the treatment of OPSCC cells with 
TLR 5 antagonists and TLR 7 agonists should be performed in order to 
evaluate the possible role of TLR 5 and TLR 7 signaling in tumor progression. 
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1. The treatment of OPSCC changed towards a more oncological 
approach during the study period. Survival improved in anterior-
wall disease, but in lateral-wall disease the outcome remained 
similar compared with the previous Finnish nationwide report. In 
lateral-wall disease, the prognosis was better, if the patient had a 
p16-positive primary tumor, no neck metastasis (cN0), or was 
female. In anterior-wall disease the outcome was better among 
patients who were female, had primary tumor class T1-T2, had a 
p16-positive primary tumor, or had received IMRT. 
2. The rate of RR was low both in the group treated with primary 
surgery (4.7%) and in the group receiving definitive oncological 
treatment (3.2%). Older age was the only clinical factor associated 
with regional recurrence. All RRs occurred in patients having class 
cN2b or higher. Five out of the seven recurrences occurred on the 
contralateral side of the neck. Therefore, both sides of the neck 
should be treated in all patients with cN+ disease.  
3. HR-HPV-positive and HR-HPV-negative OPSCC showed different 
TLR 7, and 9 expression patterns: TLR 7 was more expressed, and 
TLR 9 less expressed in HR-HPV-positive tumors. In addition, TLR 
7 was more expressed and TLR 5 less expressed in p16-positive 
tumors. The results suggest that HR-HPV-positive and HR-HPV-
negative OPSCC may evoke different immunological reactions.  
4. Patients having HR-HPV-positive OPSCC had worse DSS if their 
tumors had high TLR 5 expression or low TLR 7 expression. As most 
patients who carried a HR-HPV-positive OPSCC in this series were 
alive with no evidence of disease at the end of the follow-up, the 
present findings are based on a small number of events, and further 
validation will therefore be needed. 
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